NZ539217A - Bicyclic quinoline derivative compounds having antibacterial activity - Google Patents

Abstract

Bicyclic quinoline derivative compounds of formula (I) having an antibacterial activity are disclosed, wherein the variables shown in formula (I) are as defined in the specification. These compounds are suitable for treating bacterial infections.

Description

New Zealand Paient Spedficaiion for Paient Number 539217 <ef l7 1 Novel compounds with antibacterial activity Resistance to the antibiotics used currently has increased appreciably in many countries of the world in recent years 5 and in some cases has assumed alarming proportions. The main problem is that those pathogens exhibit not just a single resistance but, as a rule, multiple resistance. This is true especially of some gram-positive pathogen groups, such as staphylococci, pneumococci and enterococci 10 (S. Ewig et al.; Antibiotika-Resistenz bei Erregern ambulant erworbener Atemwegsinfektionen (Antibiotic resistance in pathogens of outpatient-acquired respiratory tract infections); Chemother. J. 2002, 11, 12-26; F. Tenover; Development and spread of bacterial resistance 15 to antimicrobial agents: an overview; Clin. Infect. Dis. 2001 Sep 15, 33 Suppl. 3, 108-115) A long-feared development has recently occurred: In the USA, the first strain of Staphylococcus aureus has been described that is not only resistant to methicillin but 20 also highly resistant to vancomycin (Centers for Disease Control and Prevention; Staphylococcus aureus resistant to vancomycin - United States, 2002; MMWR 2002, 51, 565-567). In addition to hygiene measures in hospitals, therefore, increased efforts are also required to find new anti-25 biotics that as far as possible have a novel structure and a novel mechanism of action so as to be effective against those problem bacteria.

The present invention describes new kinds of compounds 30 having anti-bacterial activity.

INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 JAN 2008 RECEIVED 2 The present invention relates to compounds of the general formula (I) : A is an oxygen, sulphur or nitrogen atom or a C1_4alkylene, C2-4alkenylene, C2-4alkynylene or Ci_4heteroalkylene group, Xi, X2, X3, X4 and X5 are each independently of the others 10 nitrogen atoms or groups of formula CR2, R1 is a hydrogen atom, a halogen atom, a hydroxy group, an alkyloxy group or a heteroalkyloxy group, R2 is a hydrogen atom, a halogen atom, or a hydroxy, alkyl, alkenyl, alkynyl or heteroalkyl group, R3 is selected from the following groups: (I) wherein n n n n n n f<2h' the radicals R4, each independently of any other(s), are a hydroxy group, a Ci-6alkyl group or a Ci-sheteroalkyl group, R5 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical, n is 0, 1, 2 or 3 and m is 0 or 2, or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.

The expression alkyl refers to a saturated, straight-chain or branched hydrocarbon group that contains from 1 to 20 20 carbon atoms, preferably from 1 to 12 carbon atoms, especially from 1 to 8 or from 1 to 6 or from 1 to 4 carbon atoms, for example a methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, n-hexyl, 2,2-dimethyl-butyl or n-octyl group.

The expressions alkenyl and alkynyl refer to at least partially unsaturated, straight-chain or branched hydrocarbon groups that contain from 2 to 20 carbon atoms, preferably from 2 to 12 carbon atoms, especially from 2 to 4 6 carbon atoms, for example an ethenyl, allyl, acetylenyl, propargyl, isoprenyl or hex-2-enyl group. Preferably, alkenyl groups have one or two (especially one) double bond(s) and alkynyl groups have one or two (especially 5 one) triple bond(s).

Furthermore, the terms alkyl, alkenyl and alkynyl refer to groups in which -one or more hydrogen atoms have been replaced by a halogen atom (preferably F or CI) such as, 10 for example, a 2,2,2-trichloroethyl or a trifluoromethyl group.

The expression heteroalkyl refers to an alkyl, alkenyl or alkynyl group in which one or more (preferably 1, 2 or 3) 15 carbon atoms have been replaced by an oxygen, nitrogen, phosphorus, boron, selenium, silicon or sulphur atom (preferably oxygen, sulphur or nitrogen). The expression heteroalkyl furthermore refers to a carboxylic acid or to a group derived from a carboxylic acid such as, for 20 example, acyl, acylalkyl, alkoxycarbonyl, acyloxy, acyloxyalkyl, carboxyalkylamide or alkoxycarbonyloxy.

Examples of heteroalkyl groups are groups of formulae Ra-0-Ya-, Ra-S-Ya-, Ra-N (Rb) -Ya-, Ra-CO-Ya-, Ra-0-C0-Ya-, 25 Ra-C0-0-Ya-, Ra-C0-N (Rb) -Ya-, Ra-N (Rb) -C0-Ya-, Ra-0-C0-N (Rb)-Ya-, Ra-N (Rb)-CO-O-Y3-, Ra-N (Rb) -CO-N (Rc)-Ya-, Ra-0-C0-0-Ya-, Ra-N(Rb)-C(=NRd)-N(Rc)-Ya-, Ra-CS-Ya-, Ra-0-CS-Ya-, Ra-CS-0-Ya-, Ra-CS-N (Rb)-Ya-, Ra-N (Rb) -CS-Ya-, Ra-0-CS-N (Rb)-Ya-, Ra-N(Rb)-CS-0-Ya-, Ra-N (Rb) -CS-N (Rc)-Ya-, 30 Ra-0-CS-0-Ya-, Ra-S-CO-Ya-, Ra-CO-S-Ya-, Ra-S-CO-N (Rb)-Ya-, Ra-N (Rb)-CO-S-Y3-, Ra-S-C0-0-Ya-, Ra-0-C0-S-Ya-, Ra-S-CO-S-Ya-, Ra-S-CS-Ya-, Ra-CS-S-Ya-, Ra-S-CS-N (Rb)-Ya-, Ra-N (Rb)-CS-S-Ya-, Ra-S-CS-0-Ya-, Ra-0-CS-S-Ya-, Ra being a hydrogen atom, a Ci-C6alkyl, a C2_C6alkenyl or a C2-C6-alkynyl group; Rb being a hydrogen atom, a Ci-C6alkyl, a C2-C6alkenyl or a C2-C6alkynyl group; R° being a hydrogen 5 atom, a Ci~C6alkyl, a C2-C6alkenyl or a C2-C6alkynyl group; Rd being a hydrogen atom, a Ci-C6alkyl, a C2-C6alkenyl or a C2-C6alkynyl group and Ya being a direct bond, a Ci-C6-alkylene, a C2-C6alkenylene or a C2-C6alkynylene group, each heteroalkyl group containing at least one carbon atom 10 and it being possible for one or more hydrogen atoms to have been replaced by fluorine or chlorine atoms. Specific examples of heteroalkyl groups are methoxy, trifluoromethoxy, ethoxy, n-propyloxy, isopropyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, methoxyethyl, 15 methylamino, ethylamino, dimethylamino, diethylamino, isopropylethylamino, methylaminomethyl, ethylaminomethyl, diisopropylaminoethyl, enol ether, dimethylaminomethyl, dimethylaminoethyl, acetyl, propionyl, butyryloxy, acetyloxy, methoxycarbonyl, ethoxycarbonyl, N-ethyl-N-20 methylcarbamoyl and N-methylcarbamoyl. Further examples of heteroalkyl groups are nitrile, isonitrile, cyanate, thiocyanate, isocyanate, isothiocyanate and alkylnitrile groups.

The expression cycloalkyl refers to a saturated or partially unsaturated (e.g. cycloalkenyl) cyclic group that contains one or more rings (preferably 1 or 2) containing from 3 to 14 ring carbon atoms, preferably from 3 to 10 (especially 3, 4, 5, 6 or 7) ring carbon atoms. 30 The expression cycloalkyl refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, 6 SH, =S, NH2, =NH or N02 groups, thus, for example, cyclic ketones such as, for example, cyclohexanone, 2-cyclo-hexenone or cyclopentanone. Further specific examples of cycloalkyl groups are a cyclopropyl, cyclobutyl, cyclo-5 pentyl, spiro[4,5]decanyl, norbornyl, cyclohexyl, cyclo-pentenyl, cyclohexadienyl, decalinyl, cubanyl, bicyclo-[4.3.0]nonyl, tetralin, cyclopentylcyclohexyl, fluoro-cyclohexyl or cyclohex-2-enyl group.

The expression heterocycloalkyl refers to a cycloalkyl group as defined above in which one or more (preferably 1, 2 or 3) ring carbon atoms have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulphur atom (preferably oxygen, sulphur or nitrogen). A heterocyclo- alkyl group has preferably 1 or 2 ring(s) containing from 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms. The expression heterocycloalkyl refers furthermore to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, SH, =S, NH2, =NH or N02 groups. Examples are a piperidyl, morpholinyl, urotropinyl, pyrrolidinyl, tetrahydrothio-phenyl, tetrahydropyranyl, tetrahydrofuryl, oxacyclo-propyl, azacyclopropyl or 2-pyrazolinyl group and also lactams, lactones, cyclic imides and cyclic anhydrides.

The expression alkylcycloalkyl refers to groups containing both cycloalkyl and also alkyl, alkenyl or alkynyl groups in accordance with the above definitions, for example alkylcycloalkyl, alkylcycloalkenyl, alkenylcycloalkyl and alkynylcycloalkyl groups. An alkylcycloalkyl group preferably contains a cycloalkyl group that contains one or two rings systems having from 3 to 10 (especially 3, 4, 7 , 6 or 7) ring carbon atoms, and one or two alkyl, alkenyl or alkynyl groups having 1 or 2 to 6 carbon atoms.

The expression heteroalkylcycloalkyl refers to alkylcyclo-5 alkyl groups as defined above in which one or more (preferably 1, 2 or 3) carbon atoms have been replaced by an oxygen, nitrogen, silicon, selenium, phosphorus or sulphur atom (preferably oxygen, sulphur or nitrogen). A heteroalkylcycloalkyl group preferably contains 1 or 2 10 ring systems having from 3 to 10 (especially 3, 4, 5, 6 or 7) ring atoms, and one or two alkyl, alkenyl, alkynyl or heteroalkyl groups having 1 or 2 to 6 carbon atoms. Examples of such groups are alkylheterocycloalkyl, alkyl-heterocycloalkenyl, alkenylheterocycloalkyl, alkynyl-15 heterocycloalkyl, heteroalkylcycloalkyl, heteroalkyl-heterocycloalkyl and heteroalkylheterocylcloalkenyl, the cyclic groups being saturated or mono-, di- or tri-unsaturated.

The expression aryl or Ar refers to an aromatic group that has one or more rings containing from 6 to 14 ring carbon atoms, preferably from 6 to 10 (especially 6) carbon atoms. The expression aryl (or Ar) refers furthermore to groups in which one or more hydrogen atoms have been 25 replaced by fluorine, chlorine, bromine or iodine atoms or by OH, SH, NH2 or N02 groups. Examples are a phenyl, naphthyl, biphenyl, 2-fluorophenyl, anilinyl, 3-nitro-phenyl or 4-hydroxyphenyl group.

The expression heteroaryl refers to an aromatic group that has one or more rings and is formed by a ring system that contains from 5 to 14 ring atoms, preferably from 5 to 10 8 (especially 5 or 6) ring atoms, and contains one or more (preferably 1, 2, 3 or 4) oxygen, nitrogen, phosphorus or sulphur ring atoms (preferably 0, S or N). The expression heteroaryl refers furthermore to groups in which one or 5 more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, SH, NH2 or N02 groups. Examples are 4-pyridyl, 2-imidazolyl, 3-phenyl-pyrrolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl, isoxazolyl, indazolyl, indolyl, benzimidazolyl, pyrid-10 azinyl, quinolinyl, purinyl, carbazolyl, acridinyl, pyrimidyl, 2,3'-bifuryl, 3-pyrazolyl and isoquinolinyl groups.

The expression aralkyl refers to groups containing both 15 aryl and also alkyl, alkenyl, alkynyl and/or cycloalkyl groups in accordance with the above definitions, such as, for example, arylalkyl, arylalkenyl, arylalkynyl, aryl-cycloalkyl, arylcycloalkenyl, alkylarylcycloalkyl and alkylarylcycloalkenyl groups. Specific examples of aralkyls are toluene, xylene, mesitylene, styrene, benzyl chloride, o-fluorotoluene, lH-indene, tetralin, dihydro-naphthalene, indanone, phenylcyclopentyl, cumene, cyclo-hexylphenyl, fluorene and indan. An aralkyl group preferably contains one or two aromatic ring systems (1 or 25 2 rings) containing from 6 to 10 carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing 1 or 2 to 6 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms.

The expression heteroaralkyl refers to an aralkyl group as defined above in which one or more (preferably 1, 2, 3 or 4) carbon atoms have been replaced by an oxygen, nitrogen, 9 silicon, selenium, phosphorus, boron or sulphur atom (preferably oxygen, sulphur or nitrogen), that is to say to groups containing both aryl or heteroaryl and also alkyl, alkenyl, alkynyl and/or heteroalkyl and/or cyclo-5 alkyl and/or heterocycloalkyl groups in accordance with the above definitions. A heteroaralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) containing 5 or 6 to 10 carbon atoms and one or two alkyl, alkenyl and/or alkynyl groups containing 1 or 2 to 6 10 carbon atoms and/or a cycloalkyl group containing 5 or 6 ring carbon atoms, 1, 2, 3 or 4 or those carbon atoms having been replaced by oxygen, sulphur or nitrogen atoms.

Examples are arylheteroalkyl, arylheterocycloalkyl, aryl-15 heterocycloalkenyl, arylalkylheterocycloalkyl, aryl-alkenylheterocycloalkyl, arylalkynylheterocycloalkyl, arylalkylheterocycloalkenyl, heteroarylalkyl, heteroaryl-alkenyl, heteroarylalkynyl, heteroarylheteroalkyl, hetero-arylcycloalkyl, heteroarylcycloalkenyl, heteroarylhetero-20 cycloalkyl, heteroarylheterocycloalkenyl, heteroarylalkyl-cycloalkyl, heteroarylalkylheterocycloalkenyl, heteroaryl-heteroalkylcycloalkyl, heteroarylheteroalkylcycloalkenyl and heteroarylheteroalkylheterocycloalkyl groups, the cyclic groups being saturated or mono-, di- or tri-25 unsaturated. Specific examples are a tetrahydroiso-quinolyl-, benzoyl-, 2- or 3-ethylindolyl-, 4-methyl-pyridino-, 2-, 3- or 4-methoxyphenyl-, 4-ethoxyphenyl-, 2-, 3- or 4-carboxyphenyl-alkyl group.

The expressions cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl refer to groups in which one or more hydrogen atoms of such groups have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, SH, =S, NH2, =NH or N02 groups.

The expression "optionally substituted" refers to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or by OH, =0, SH, =S, NH2, =NH or N02 groups. The expression refers furthermore to groups that are substituted by 10 unsubstituted Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6heteroalkyl, C3-Ci0cycloalkyl, C2-C9heterocycloalkyl, C6~Cioaryl, Ci-Cgheteroaryl, C7-Ci2aralkyl or C2-Cnhetero-aralkyl groups.

Owing to their substitution, compounds of formula (I) may contain one or more centres of chirality. The present invention therefore includes both all pure enantiomers and all pure diastereoisomers and also mixtures thereof in any mixing ratio. The present invention moreover also 20 includes all cis/trans-isomers of the compounds of the general formula (I) and also mixtures thereof. The present invention moreover includes all tautomeric forms of the compounds of formula (I).

Preferred are compounds of formula (I) wherein A is an oxygen atom or a group of formula CH2 or CH(OH).

Also preferred are compounds of formula (I) wherein one of the groups Xi, X2, X3, X4 and X5 (especially Xi or X2) is a 30 nitrogen atom and the others are CH groups, or all of the groups Xi, X2, X3, X4 and X5 are CH groups. 11 Furthermore, R3 is preferably one of the following groups: R5 ^0,Ri R1 is especially preferably a halogen atom, a Ci-6alkyloxy 5 group (for example methoxy or ethoxy), a methyl group or an ethyl group; especially a methoxy group.

Also preferably, R4 is a Ci-6heteroalkyl group, as defined hereinabove, having one or two oxygen atoms as individual 10 hetero atoms.

R4 is especially preferably a group of formula -cooh, -ch2cooh, -ch2ch2cooh, -ch2cooch3, -ch2ch3, -ch2oh, -ch2ch2oh, -oh, -och3, -ch2oconh2, -ch2ch2cooch3, -cooch3, —CH3 or -(CH2)3OH.

Also preferably, n is 0 or 1.

Also preferably, R5 is an aralkyl or a hetero-aralkyl 20 group.

Again preferably, R5 is a group of formula -Y-Cy, Y being a Ci-C6alkylene, C2-C6alkenylene or Ci-C6heteroalkylene group, wherein optionally a hydrogen atom may have been 25 replaced by a hydroxy group or two hydrogen atoms may have been replaced by an =0 group, and Cy being an optionally substituted phenyl, naphthyl or heteroaryl group containing 1 or 2 rings and from 5 to 10 ring atoms, or an optionally substituted arylheterocycloalkyl or heteroaryl- 12 heterocycloalkyl group containing two rings and 9 or 10 ring atoms.

The therapeutic use of compounds of formula (I), their 5 pharmacologically acceptable salts or solvates and hydrates and also formulations and pharmaceutical ".. compositions also lie within the scope of the present invention.

The pharmaceutically compositions according to the present invention comprise at least one compound of formula (I) as active ingredient and, optionally, carrier substances and/or adjuvants.

Examples of pharmacologically acceptable salts of the compounds of formula (I) are salts of physiologically acceptable mineral acids, such as hydrochloric acid, sulphuric acid and phosphoric acid, and salts of organic acids, such as methanesulphonic acid, p-toluenesulphonic 20 acid, lactic acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, oxalic acid, maleic acid and salicylic acid. Further examples of pharmacologically acceptable salts of the compounds of formula (I) are alkali metal and alkaline earth metal 25 salts such as, for example, sodium, potassium, lithium, calcium and magnesium salts, ammonium salts and salts of organic bases such as, for example, methylamine, dimethylamine, triethylamine, piperidine, ethylenediamine, lysine, choline hydroxide, meglumine, morpholine and 30 arginine salts. Compounds of formula (I) can be solvated, especially hydrated. The hydration may take place, for example, during the preparation process or as a 13 consequence of the hygroscopic nature of the initially anhydrous compounds of formula (I). When the compounds of formula (I) comprise asymmetric carbon atoms, they may be either in the form of achiral compounds, diastereoisomeric 5 mixtures, mixtures of enantiomers or in the form of optically pure compounds.

The pro-drugs to which the present invention also relates consist of a compound of formula (I) and at least one 10 pharmacologically acceptable protecting group that is removed under physiological conditions, for example an alkoxy, aralkyloxy, acyl or acyloxy group, such as, for example, an ethoxy, daloxate, benzyloxy, acetyl or acetyloxy group or a group of formula COOCH2OCOC (CH3) 3 or 15 C00CH20C00-cyclohexyl.

The present invention relates also to the use of those active ingredients in the preparation of medicaments. In general, compounds of formula (I) are administered either 20 individually, or in combination with any other desired therapeutic agent, using the known and acceptable methods. Such therapeutically useful agents may be administered, for example, by one of the following routes: orally, for example in the form of dragees, coated tablets, pills, 25 semi-solid substances, soft or hard capsules, solutions, emulsions or suspensions; parenterally, for example in the form of an injectable solution; rectally in the form of suppositories; by inhalation, for example in the form of a powder formulation or spray, transdermally or 30 intranasally. For the preparation of such tablets, pills, semi-solid substances, coated tablets, dragees and hard gelatin capsules, the therapeutically usable product can 14 be mixed with pharmacologically inert, inorganic or organic pharmaceutical carrier substances, for example with lactose, sucrose, glucose, gelatin, malt, silica gel, starch or derivatives thereof, talcum, stearic acid or 5 salts thereof, skimmed milk powder and the like. For the preparation of soft capsules, pharmaceutical carrier substances such as, for example, vegetable oils, petroleum, animal or synthetic oils, wax, fat and polyols can be used. For the preparation of liquid solutions and 10 syrups, pharmaceutical carrier substances such as, for example, water, alcohols, aqueous saline solution, aqueous dextrose, polyols, glycerol, vegetable oils, petroleum and animal or synthetic oils can be used. For suppositories, pharmaceutical carrier substances such as, for example, 15 vegetable oils, petroleum, animal or synthetic oils, wax, fat and polyols can be used. For aerosol formulations, compressed gases that are suitable for the purpose can be used, such as, for example, oxygen, nitrogen and carbon dioxide. The pharmaceutically acceptable agents may also 20 comprise additives for preserving and stabilising, emulsifiers, sweeteners, flavourings, salts for altering the osmotic pressure, buffers, encapsulation additives and anti-oxidants.

Combinations with other therapeutic agents may comprise other antimicrobial and anti-fungal active ingredients.

For the prevention and/or treatment of bacterial infections, the dose of the biologically active compound 30 according to the invention can vary within wide limits and can be adjusted to individual requirements. Generally, a dose of from 10 mg to 4000 mg per day is suitable, a preferred dose being from 50 to 3000 mg per day. In suitable cases, the dose may also be below or above the stated values. The daily dose can be administered as a single dose or in a plurality of doses. A typical 5 individual dose contains approximately 50 mg, 100 mg, 250 mg, 500 mg, 1 g or 2 g of the active ingredient.

Example 1: 2-((3RS)-{[(2,3-Dihydro-benzo[1,4]dioxin-6-yl-methyl)amino]methyl}piperidin-l-yl)-(IRS)-(6-methoxy-quinolin-4-yl)ethanol. l.a) Benzyl (3RS)-azidomethylpiperidine-l-carbamate: At 0°C, triethylamine (5.6 ml, 40.1 mmol) and then 20 methanesulphonyl chloride (2 ml, 25.7 mmol) were added to a solution of benzyl 3-hydroxymethylpiperidine-l-carbamate (5 g, 20.05 mmol) in dichloromethane (100 ml). After the solution had been stirred for 20 min., the reaction mixture was cooled to -60°C and a solution of benzyl 25 4-oxopiperidine-l-carbamate (2.33 g, 10 mmol) in diethyl ether (10 ml) was added. The reaction mixture was heated to room temperature in the course of 30 minutes and water (40 ml) was added. The two phases were separated and the aqueous phase was extracted twice using 50 ml of ethyl EXAMPLES O 16 acetate each time. The combined organic phases were washed with 20 ml of saturated sodium chloride solution, dried over MgSC>4, filtered and concentrated to dryness by rotary evaporation. The residue was purified by column 5 chromatography on silica gel (EtOAc). The resulting oil was dissolved in DMF (45 ml), and sodium azide (2.6 g, 40 mmol) was added. The reaction mixture was further stirred for 3 hours at 80°C and then diluted with water (100 ml) and ethyl acetate (200 ml) . The two phases were 10 separated and the aqueous phase was extracted twice using 50 ml of ethyl acetate each time. The combined organic phases were washed with 20 ml of saturated sodium chloride solution, dried over MgS04, filtered and concentrated to dryness by rotary evaporation. The residue was purified by 15 column chromatography on silica gel (hexane/EtOAc 1/1).

Yield: 6.1 g (18.6 mmol) 1H-NMR (CDC13, 300 MHz: 1.28 (m, 1H) ; 1.51 (m, 1H) ; 1.60-1.87 (m, 3H); 2.74 (br s, 1H) ; 2.91 (m, 1H); 3.23 (br d, <J= 4.5 Hz, 2H); 3.98 (td, J= 4.1, 13.2 Hz, 1H); 20 4.06 (br s, 1H); 5.15 (s, 2H); 7.28-7.38 (m, 5H).

Benzyl 3-hydroxymethyl-piperidine-l-carbamate has already been described in Arch. Pharm. (Weinheim, Germany) 1990 p. 9-12. l.b) Benzyl (3RS)-aminomethyl-piperidine-l-carbamate: o Triphenylphosphine (8 g, 30 mmol) was added to a solution 30 of benzyl 3-azidomethylpiperidine-l-carbamate (6.1 g, 17 18.6 mmol) in THF (37 ml) and water (5 ml). After the solution had been stirred for 3 hours at 60°C, the reaction mixture was concentrated and the residue was taken up in 3N HC1 (200 ml) and ether (200 ml) . The two 5 phases were separated and the aqueous phase was extracted twice using 100 ml of ethyl acetate each time. Solid sodium hydroxide (16 g, 640 mmol) was cautiously added until an oil separated out. The mixture was diluted with ethyl acetate and the organic phases was dried over MgS04 10 and filtered, and the filtrate was concentrated to dryness by rotary evaporation.

Yield: 2.81 g, 11.3 mmol MS (EI) m/z 249 [M+H]+ l.c) Benzyl (3RS)-{[(2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-amino]-methyl}-piperidine-l-carbamate: o 1,4-Benzodioxane-6-carbaldehyde (0.984 g, 6 mmol) and sodium triacetoxyborohydride (1.7 g, 8 mmol) were added to a solution of benzyl 3-aminomethylpiperidine-l-carbamate (1.5 g, 6 mmol) in dichloroethane (37 ml) and THF (4 ml). After the solution had been stirred at room temperature 25 for 3 hours, saturated NaHCC>3 solution (20 ml) was added. The two phases were separated and the aqueous phase was extracted twice using 50 ml of dichloromethane each time. The combined organic phases were washed with 20 ml of saturated sodium chloride solution, dried over MgS04, 30 filtered and concentrated to dryness by rotary 18 evaporation. The residue was purified by column chromatography on silica gel (EtOAc and then MeOH/EtOAc 1/9) .

Yield: 1.7 g, 4.28 mmol (oil) MS (EI) m/z 397 [M+H]+ 1.d (2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-piperidin-(3RS)-yl-methylamine: cX»-XO H % Pd(OH)2 on carbon (0.23 g) was added to a solution of benzyl 3-{[(2,3-dihydrobenzo[1,4]dioxin-6-yl-methyl)- amino]methyl}piperidine-l-carbamate (0.98 g, 2.47 mmol) in EtOH (10 ml) and EtOAc (10 ml) and hydrogenation was 15 carried out under a hydrogen atmosphere (1 bar). The reaction mixture was filtered and the filtrate was concentrated.

Yield: 0.64 g, 2.43 mmol MS (EI) m/z 308 [M+H] + 1.e) (RS)-6-Methoxy-4-oxiranylquinoline: Trimethylsulphonium iodide (0.954 g, 4.67 mmol) and 25 potassium hydroxide powder (1.8 g, 32 mmol) were added to a solution of 6-methoxyquinoline-4-carbaldehyde (0.85 g, 4.54 mmol) in acetonitrile (13.5 ml) and water (6 drops). 19 The reaction mixture was heated at 60°C for one hour. The mixture was then cooled to room temperature and benzene (40 ml) was added. The precipitate was filtered off and the filtrate was concentrated to dryness by rotary 5 evaporation. The residue was diluted with water (100 ml) and ethyl acetate (100 ml), the phases were separated, and the aqueous phase was extracted twice using 50 ml of ethyl acetate each time. The combined organic phases were dried over MgS04, filtered and concentrated to dryness by rotary 10 evaporation. The residue was purified by column chromatography on silica gel (EtOAc). 6-Methoxyquinoline-4-carbaldehyde was prepared according to Eur. J. Med: Chem. Chim. Ther. 2000 (35) p-707-714. 1.f) 2-((3RS)-{[(2,3-Dihydrobenzo[1,4]dioxin-6-ylmethyl)-amino]-methyl}-piperidin-l-yl)-(IRS)-(6-methoxyquinolin-4-20 yl)ethanol: A solution of (RS)-6-methoxy-4-oxiranylquinoline (0.161 g, 25 0.8 mmol) and (2,3-dihydrobenzo[1, 4]dioxin-6-ylmethyl)-piperidin-(3RS)-ylmethylamine (0.210 g, 0.8 mmol) in ethanol (4 ml) was heated at 80°C for 16 hours. The reaction mixture was cooled to room temperature and concentrated to dryness by rotary evaporation. The residue Yield: 0.904 g, 4.5 mmol MS (EI) m/z 202 [M+H]+ was purified by column chromatography on silica gel (EtOAc and then EtOAc/MeOH 4:1).

Yield: 0.240 g. 0.51 mmol (oil) MS (EI) m/z 464 [M+H]+ Example 2: (IRS)-(6-Methoxy-quinolin-4-yl)-2-((3RS)-{[(naphth-2-ylmethyl)-amino]-methyl}-piperidin-l-yl)-ethanol 2.a) Benzyl (3RS)-(tert-butoxycarbonylamino-methyl)-piperidine-l-carbamate Triethylamine (5.6 ml) and di-tert-butyl dicarbonate (4.9 g, 22.4 mmol) were added to a solution of benzyl 3-15 aminomethylpiperidine-l-carbamate (5 g, 20.1 mmol) in dichloromethane (100 ml) . After the solution had been stirred at room temperature for 4 hours, the solution was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel 20 (EtOAc/hexane 1/4).

Yield: 5.0 g, 14.3 mmol (oil) MS (EI) m/z 349 [M+H]+ 2.b) tert-Butyl (RS)-piperidin-3-ylmethylcarbamate 0 o H 21 t % Pd(OH)2 on carbon (1 g) was added to a solution of benzyl 3-(tert-butoxycarbonylamino-methyl)-piperidine-l-carbamate (5 g, 14.3 mmol) in EtOH (50 ml) and EtOAc (50 ml), and hydrogenation was carried out under a 5 hydrogen atmosphere (1 bar). The reaction mixture was filtered and the filtrate was concentrated. 2.c) tert-Butyl {1-[(2RS)-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-(3RS)-ylmethyl}carbamate A solution of 6-methoxy-4-oxiranylquinoline (2.68 g, 13.3 mmol) and tert-butyl piperidin-3-ylmethylcarbamate 15 (2.85 g, 13.3 mmol) in ethanol (35 ml) was heated at 80°C for 12 hours. The reaction mixture was cooled to room temperature and concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 9:1).

Yield: 2.49 g. 6 mmol (foam) MS (EI) m/z 416 [M+H]+ 2.d) 2-((3RS)-Aminomethyl-piperidin-l-yl)-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol Yield: 3.0 g, 14 mmol (oil) MS (EI) m/z 215 [m+h]+ 22 A solution of tert-butyl {1-[2-hydroxy-2-(6-methoxy-quin-olin-4-yl)-ethyl]-piperidin-3-ylmethyl}carbamate (2.49 g, 6 mmol) in TFA (10 ml) was stirred at room temperature for 5 20 minutes. The reaction mixture was concentrated and taken up in aqueous 2N NaOH. The aqueous phase was extracted with dichloromethane/MeOH (9/1), and the combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness by rotary evapora-10 tion. 2.e) (IRS)-(6-Methoxy-quinolin-4-yl)-2-((3RS)-{[(naphth-2-15 ylmethyl)-amino]-methyl}-piperidin-l-yl)-ethanol Molecular sieve, type 3A, (1 g) and 2-naphthaldehyde (0.078 g, 0.5 mmol) were added to a solution of 2— (3— aminomethyl-piperidin-l-yl)-1-(6-methoxy-quinolin-4-yl)-20 ethanol (0.158 g, 0.5 mmol) in MeOH (1.5 ml) and dichloromethane (3.5 ml). The reaction mixture was stirred at room temperature for 16 hours and sodium borohydride (0.05 g, 1.35 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours and then filtered 25 over Hydromatrix (wetted with a NaHCC>3 solution, 2 ml) and subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 9/1 1% NH4OH).

Yield: 1.7 g. 5.4 mmol (foam) MS (EI) m/z 316 [M+H]+ 23 Yield:0.158 g. (0.34 mmol) (foam) MS (EI) m/z 456 [M+H]+ Example 3: (IRS)-(6-Methoxy-quinolin-4-yl)-2-{(3RS)-[(3-5 phenyl-allylamino)-methyl]-piperidin-l-yl}-ethanol In an analogous manner, starting from Example 2.e, (1RS)-(6-methoxy-quinolin-4-yl)-(2RS)-{3-[(3-phenyl-allylamino)-10 methyl]-piperidin-l-yl}-ethanol was produced in a yield of 74% (MS (EI) m/z 432 [M+H]+).

Example 4: 2-{(3RS)-[(3-Furan-2-yl-allylamino)-methyl]-piperidin-l-yl}-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol In an analogous manner, starting from Example 2.e, 2—{3—[(3-furan-2-yl-allylamino)-methyl]-piperidin-l-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol was produced in a yield 20 of 56% (MS (EI) m/z 422 [M+H]+). 24 Example 5: (3S)-6-[({1-[2-Hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-(3RS)-ylmethyl}-amino)-methyl]-4H-benzo[1,4]oxazin-3-one 5a) tert-Butyl (3S)-aminomethyl-piperidine-l-carbamate N 0^0 Triphenylphosphine (3.93 g, 15 mmol) was added to a solution of tert-butyl (3R)-azidomethyl-piperidine-1-carbamate (2.16 g, 8.9 mmol) in THF (60 ml) and water 10 (5 ml) . After the solution had been stirred at 60°C for 3 hours, the reaction mixture was concentrated and the residue was taken up in 3N HC1 (200 ml) and ether (200 ml) . The two phases were separated and the aqueous phase was extracted twice using 100 ml of ethyl acetate 15 each time. Solid sodium hydroxide (6 g, 150 mmol) was cautiously added until an oil separated out. The mixture was diluted with ethyl acetate, the organic phase was dried over MgS04 and filtered and the filtrate was concentrated to dryness by rotary evaporation. 20 Yield: 1.90 g, 8.8 mmol MS (EI) m/z 215 [M+H]+ tert-Butyl 3R-azidomethyl-piperidine-l-carbamate was prepared according to J. Med. Chem. 1994 (37) p. 3889-3901 .b) tert-Butyl 3S-(benzyloxycarbonylamino-methyl)-piper-idine-1-carbamate Sodium bicarbonate (1.3 g, 15.4 mmol) and chloroformic 5 acid benzyl ester (1.3 ml, 9 mmol) were added to a solution of tert-butyl 3S-aminomethyl-piperidine-l-carbamate (1.90 g, 8.8 mmol) in acetone/water (1/1, 100 ml). The reaction mixture was stirred for one hour and then concentrated to dryness by rotary evaporation. The 10 residue was diluted with EtOAc (100 ml) . The two phases were separated and the aqueous phase was extracted twice using 50 ml of EtOAc each time. The combined organic phases were washed with 20 ml of saturated sodium chloride solution, dried over MgS04, filtered and concentrated to 15 dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (EtOAc/hexane 1/2). Yield: 2.96 g , 8.5 mmol (oil) MS (EI) m/z 349 [M+H]+ 5.c) Benzyl piperidin-(3R)-ylmethylcarbamate A solution of tert-butyl 3S-(benzyloxycarbonylamino-methyl) -piperidine-l-carbamate (2 . 96 g, 6 mmol) in TFA (10 ml) was stirred at room temperature for 20 minutes. 25 The reaction mixture was concentrated and taken up in aqueous 2N NaOH. The aqueous phase was extracted with o o 26 dichloromethane/MeOH (9/1), and the combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness by rotary evaporation.

Yield: 1.96 g. 7.9 mmol (foam) MS (EI) m/z 249 [M+H]+ .d) Benzyl {1-[(2RS)-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-(3R)-ylmethyl}carbamate o Potassium carbonate (1.12 g, 8.10 mmol) and lithium perchlorate (0.627 g, 5.89 mmol) were added to a solution of 6-methoxy-4-oxiranylquinoline (1.127 g, 5.60 mmol) and benzyl piperidin-3-ylmethylcarbamate (1.46 g, 5.88 mmol) in DMF (17 ml) . The reaction mixture was heated at 60°C 15 for 16 hours and then cooled to room temperature and concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 9:1 1% ammonium hydroxide).

Yield: 2.51 g. 5.58 mmol (oil) MS (EI) m/z 450 [M+H]+ .e) (3S)-2-(3-Aminomethyl-piperidin-l-yl)-(IRS)-methoxy-quinolin-4-yl)-ethanol NH, 6- 27 % Pd(OH)2 on carbon (0.7 g) was added to a solution of benzyl {1-[2-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-3-ylmethyl}carbamate (2.51 g, 5.58 mmol) in THF (35 ml) , MeOH (7 ml) was added and hydrogenation was 5 carried out under a hydrogen atmosphere (1 bar). The reaction mixture was filtered and the filtrate was concentrated. .f) (3S)-6-[({1-[(2RS)-Hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-3-ylmethyl}-amino)-methyl]-4H-benzo[1,4]oxazin-3-one Molecular sieve, type 3A, (1.082 g) and 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carbaldehyde (0.095 g, 0.54 mmol) were added to a solution of (3S)-2-(3-aminomethyl-piperidin-l-yl)-1-(6-methoxy-quinolin-4-yl)-ethanol (0.171 g, 0.54 mmol) in MeOH (1.6 ml) and dichloromethane 20 (3.8 ml). The reaction mixture was stirred at room temperature for 16 hours and sodium borohydride (0.054 g, 1.43 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours and then filtered over Hydromatrix (wetted with an NaHC03 solution, 2 ml) and 25 subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 9/1 1% NH4OH).

Yield: 1.76 g. 5.58 mmol (oil) MS (EI) m/z 316 [M+H]+ O 28 Yield:0.112 g. (0.24 mmol) (foam) MS (EI) m/z 477 [M+H]+ 3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carbaldehyde was prepared according to WO 02/34754.

Example 6: (3S)-2-(3-{[(Benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-methyl}-piperidin-l-yl)-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol Starting from (3S)-2-(3-aminomethyl-piperidin-l-yl)-1-(6-methoxy-quinolin-4-yl)-ethanol (Example 5.e), (3S)-2-(3-{[(benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-methyl}-piperidin-l-yl)-1-(6-methoxy-quinolin-4-yl)-ethanol was produced in an analogous manner in a yield of 4 9% (MS (EI) m/z 464 [M+H]+) .

Example 7: 2-((3S)-{[(2,3-Dihydro-benzo[1,4]dioxepin-6-ylmethyl)-amino]-methyl}-piperidin-l-yl)-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol 29 Starting from (3S)-2-(3-aminomethyl-piperidin-l-yl)-1-(6-methoxy-quinolin-4-yl)-ethanol (Example 5.e), 2-((3S)-{[(2,3-dihydro-benzo[1,4]dioxepin-6-ylmethyl)-amino]-methyl}-piperidin-l-yl)-(IRS)-(6-methoxy-quinolin-4-yl)-5 ethanol was produced in an analogous manner in a yield of 62% (MS (EI) m/z 478 [M+H]+). 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carbaldehyde was prepared according to Chem.Abstr 1958, 3816.

Example 8: 2-((3S)-{[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-methyl}-piperidin-l-yl)-(IS)-(6-methoxy-quinolin-4-yl)-ethanol 8.a) tert-Butyl (3S)-{[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-methyl}-piperidine-l-carbamate Molecular sieve, type 3A, (9.6 g) and 2,3-dihydrobenzo [1,4]dioxin-6-carbaldehyde (0.078 g, 0.5 mmol) were 20 added to a solution of tert-butyl 3S-aminomethyl-piperidine-l-carbamate (Example 5.a) (0.158 g, 0.5 mmol) in MeOH (8 ml) and dichloromethane (27 ml) . The reaction mixture was stirred at room temperature for 16 hours and sodium borohydride (0.05 g, 1.35 mmol) was added. The 25 reaction mixture was stirred at room temperature for 2 hours and then filtered over Hydromatrix (wetted with an O A o NaHC03 solution, 20 ml) and subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 19/1). 5 Yield: 2.2 g. 6.0 mmol (foam) MS (EI) m/z 363.4 [M+H]+ 8.b) (R)-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-piperidin-3-ylmethyl-amine A solution of tert-butyl 3S-{[(2,3-dihydro-benzo[1, 4]-dioxin-6-ylmethyl)-amino]-methyl}-piperidine-l-carbamate (2.2 g, 6 mmol) in TFA (10 ml) was stirred at room temperature for 20 minutes. The reaction mixture was concen-15 trated and taken up in aqueous 2N NaOH. The aqueous phase was extracted with dichloromethane/MeOH (9/1), and the combined organic phases were dried over sodium sulphate, filtered and concentrated to dryness by rotary evaporation.

Yield: 1.18 g, 4.53 mmol (foam) MS (EI) m/z 263.4 [M+H]+ 31 8.c) 2-((3S)-{[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-methyl}-piperidin-l-yl)-(IS)-(6-methoxy-quinolin-4-yl)-ethanol The title compound was produced in a manner analogous to Example l.f in a yield of 36% (MS (EI) m/z 464.5 [M+H]+).

(R)— 6—Methoxy — 4 —oxirany1quinoline was prepared analogously to WO 02/50040. 0 Example 9: 2-((3S)-{[(2,3-Dihydro-benzo[1,3]dioxo-6-ylmethyl)-amino]-methyl}-piperidin-l-yl)-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol The title compound was produced in a manner analogous to Example If in a yield of 44% (MS (EI) m/z 450 [M+H]+). 32 Example 10: 4-[(Benzo[1.3]dioxol-5-ylmethyl)-amino]-1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol .a) 8-([2-(6-Methoxy-quinazolin-4-yl)-ethyl]-1,4-5 dioxaspiro-[4.5]decan-8-ol Platinum oxide (0.46 g) was added to a solution of 8-(6-10 methoxy-quinazolin-4-ylethynyl)-1,4-dioxa-spiro[4.5]decan-8-ol (0.96 g, 2.88 mmol) in EtOH (40 ml) and THF (10 ml), and hydrogenation was carried out under a hydrogen atmosphere (1 bar) . The reaction mixture was stirred in the presence of activated carbon (5 g) and filtered. The 15 filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (EtOAc and then EtOAc:MeOH 9/1) . 8-(6-Methoxy-quinazolin-4-ylethynyl)-1,4-dioxa-spiro-[4.5]decan-8-ol was prepared according to J. Chem. Soc. Perk. Trans. 1, 2000, 3382.

Yield: 0.623 g (1.81 mmol), foam MS (EI) m/z 344 [M+H] + 33 .b) 4-Hydroxy-4-[2-(6-methoxyquinazolin-4-yl)-ethyl]-cyclo-hexanone o A solution of 8-([2-(6-methoxy-quinazolin-4-yl)-ethyl] -1, 4-dioxa-spiro[4.5]decan-8-ol (0.623 g, 1.81 mmol) in ACOH/THF/H2O (3/2/2, 10 ml) was stirred at 60 °C for hours. The reaction mixture was concentrated to dryness 10 by rotary evaporation. The residue was diluted with sodium bicarbonate (100 ml) and ethyl acetate (100 ml), the phases were separated and the aqueous phase was extracted twice using 50 ml of ethyl acetate each time. The combined organic phases were dried over MgS04, filtered and 15 concentrated to dryness by rotary evaporation.

Yield: 0.425 g (1.41 mmol) foam.

MS (EI) m/z 301 [M+H]+ .c) 4-[(Benzo[1.3]dioxol-5-ylmethyl)-amino]—1—[2—(6— 20 methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol: H 34 Piperonylamine (0.030 ml, 0.24 mmol) and sodium triacetoxyborohydride (0.08 g, 0.377 mmol) were added to a solution of 4-hydroxy-4-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanone (0.06 g, 0.2 mmol) in dichloromethane 5 (1 ml). The reaction mixture was stirred overnight and then filtered over Hydromatrix (wetted with an NaHCC>3 solution, 2 ml) and subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column 10 chromatography on silica gel (dichloromethane:MeOH 9/1 and then dichloromethane:MeOH 9/1 and 2% triethylamine).

Yield: 0.074 g (0.17 mmol) cis/trans mixture MS (EI) m/z 436 [M+H]+ Example 11: 4-[(Benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol 11.a) 4-Amino-l-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol Ammonium acetate (14 g, 44 mmol) and sodium triacetoxyborohydride (1.2 g, 5 mmol) were added to a solution of 4-hydroxy-4-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanone (1.25 g, 4.2 mmol) in methanol (50 ml). The 25 reaction mixture was stirred overnight and concentrated to dryness by rotary evaporation. The residue was diluted with water (100 ml) and dichloromethane (100 ml), the phases were separated and the aqueous phase was extracted twice using 50 ml of dichloromethane each time. The combined organic phases were dried over Na2S04, filtered and concentrated to dryness by rotary evaporation.

Yield: 0.85 g. 2.82 mmol (oil) cis/trans mixture 5 MS (EI) m/z 302 [M+H]+ 11.b) 4-[(Benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol O Molecular sieve, type 3A, (1 g) and benzo [1,2,5] thia-diazol-5-carbaldehyde (0.066 g, 0.4 mmol) were added to a solution of 4-amino-l-[2-(6-methoxy-quinazolin-4-yl) -ethyl]-cyclohexanol (0.116 g, 0.38 mmol) in methanol (1 ml) and dichloroethane (3 ml). The reaction mixture was 15 stirred at room temperature for 20 hours and sodium triacetoxyborohydride (0.22 g, 1.04 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours and then filtered over Hydromatrix (wetted with an NaHCC>3 solution, 2 ml) and subsequently washed with 20 dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 9/1 1% NH4OH).

Yield: 0.112 g. 0.24 mmol (oil)cis/trans-mixture. 25 MS (EI) m/z 450 [M+H]+ 36 Example 12: 1-[2-(6-Methoxy-quinazolin-4-yl)-ethyl]-4-(3-phenyl-allylamino)-cyclohexanol HO In an analogous manner, starting from 4-amino-l-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol (Example 11.b), 1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-4-(3- phenyl-allylamino)-cyclohexanol in the form of a cis/trans mixture was produced in a yield of 54% (MS (EI) m/z 418 [M+H] +) .

Example 13: 4-(3-Furan-2-yl-allylamino)-1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol cJV-Cr" M 'J. 0H n^N In an analogous manner, starting from 4-amino-l-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol (Example 11.b), 4-(3-furan-2-yl-allylamino)-1-[2-(6-meth-oxy-quinazolin-4-yl)-ethyl]-cyclohexanol in the form of a cis/trans mixture was produced in a yield of 62% (MS (EI) m/z 408 [M+H]+) . 37 Example 14: 4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclo-hexanol In an analogous manner, starting from 4-amino-l-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol (Example 11.b), 4-[(2,3-dihydro-benzo[1,4]dioxin-6-yl- methyl)-amino]-1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-10 cyclohexanol in the form of a cis/trans mixture was produced in a yield of 68% (MS (EI) m/z 450 [M+H]+).

Example 15: 1-[2-(6-Methoxy-quinazolin-4-yl)-ethyl]-4-[(quinoxalin-2-ylmethyl)-amino]-cyclohexanol In an analogous manner, starting from 4-amino-l-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-cyclohexanol (Example 11.b), 1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]-4-20 [(quinoxalin-2-ylmethyl)-amino]-cyclohexanol in the form of a cis/trans mixture was produced in a yield of 59% (MS (EI) m/z 450 [M+H]+) . 38 Example 16: cis- and trans-4-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol 16 a) 8-(6-Methoxy-[1,5]naphthyridin-4-ylethynyl)-1,4-dioxa-spiro[4.5]decan-8-ol A degassed solution of trifluoromethanesulphonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester (986 mg, 3.2 mmol) 10 (WO 03 010138) and 8-ethynyl-l,4-dioxa-spiro[4.5]decan-8-ol (638 mg, 3.5 mmol) (prepared according to J. Chem. Soc. Perk. Trans. 1, 2000, 3382) in DMF (3 ml) was added dropwise to a likewise degassed suspension of copper(I) iodide (50 mg) and PdCl2(PPh3)2 (100 mg) in DMF (2 ml) and 15 triethylamine (3 ml). The reaction mixture was stirred at room temperature for 30 minutes and diluted with water and ether, and the organic phase was washed with water, saturated ammonium chloride solution and saturated sodium chloride solution, dried over MgS04 and concentrated. The 20 crude product was purified by chromatography on silica gel (hex/EtOAc 1:1, EtOAc).

Yield: 0.965 g. 2.8 mmol (oil).

MS (EI) m/z 341 [M+H]+ 39 16.b) 8-[2-(6-Methoxy-[1,5]naphthyridin-4-yl)-ethyl]-1,4-dioxa-spiro[4.5]decan-8-ol A solution of 8-(6-methoxy-[1,5]naphthyridin-4-ylethynyl)-1,4-dioxa-spiro[4.5]decan-8-ol (965 mg, 2.8 mmol) in ethanol (100 ml) was hydrogenated for 6 hours over PtC>2 (200 mg) at 1 bar of hydrogen. The catalyst was filtered off and replaced by fresh catalyst and the hydrogenation 10 was continued for a further 3 hours. The catalyst was filtered off and the solvent was concentrated. The crude product was purified by chromatography on silica gel (EtOAc).

Yield: 0.960 g, 2.79 mol (oil).

MS (EI) m/z 334.4 [M+H]+ 16.c) 4-Hydroxy-4-[2-(6-methoxy-[1, 5]naphthyridin-4-yl)-ethyl]-cyclohexanone A solution of 8-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-1,4-dioxa-spiro[4.5]decan-8-ol (960 mg, 2.79 mmol) in THF/H20/Ac0H (2:2:3, 22ml) was stirred overnight at 65°C. The reaction mixture was concentrated and purified by chromatography on silica gel (EtOAc). 40 Yield: 0.700 g, 2.33 mmol (oil). MS (EI) m/z 301 [M+H]+ 16.d) cis- and trans-4-[(Benzo[1, 3]dioxol-5-ylmethyl)-5 amino]-1-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol NaBH(OAc)3 (100 mg) was added to a solution of 4-hydroxy-10 4-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclo- hexanone (100 mg, 0.3 mmol) and piperonylamine (100 (0,1) in THF (3 ml) . The reaction mixture was stirred at room temperature for 4 hours, and diluted with dichloromethane and ammonium hydroxide. The organic phase was dried over 15 MgSC>4 and concentrated. The residue was purified by chromatography on silica gel (EtOAc/MeOH 9:1 +1% NH4OH) . cis-4-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol (38 mg, MS (EI) m/z 357 [M+H]+) and trans-4-[(benzo-20 [1,3]dioxol-5-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]- naphthyridin-4-yl)-ethyl]-cyclohexanol (63 mg, MS (EI) m/z 357 [M+H]+) were obtained. 41 Example 17: cis- and trans-4-[(Benzo[1,33dioxo-5-yl-methyl)-amino]-1-[2-(6-methoxy-[1,5]naphthyridin-4-yl) ethyl]-cyclohexanol 17.a) 4-[2-(6-Ethoxy-quinolin-4-yl)-ethyl]-4-hydroxy-cyclohexanone In a manner analogous to Example 16.c, 4-[2-(6-ethoxy-10 quinolin-4-yl)-ethyl]-4-hydroxy-cyclohexanone was prepared from 6-ethoxy-quinolin-4-ol. MS (EI) m/z 314 [M+H]+) 6-Ethoxyquinolin-4-ol has already been described in Synth. Comm. 2002, 32, 3185. 17.b) cis- and trans-4-[(Benzo[1,3]dioxo-5-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol In a manner analogous to Example 16.d, there were obtained cis-4-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-1-[2-(6-methoxy[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol (48% 42 yield, MS (EI) m/z 449 [M+H]+) and trans-4-[ (benzo [1,3] -dioxol-5-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]naphthyr-idin-4-yl)-ethyl]-cyclohexanol (29% yield, MS (EI) m/z 449 [M+H] +) .

Example 18: Synthesis of cis- and trans-4-[(2,3-dihydrobenzo [1,4]dioxin-6-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]— naphthyridin-4-yl)-ethyl]-cyclohexanol 18.a) 4-Amino-l-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol Sodium triacetoxyborohydride (1.89 g, 8.75 mmol) was added to a solution of 4-hydroxy-4-[2-(6-methoxy-[1,5]naph-15 thyridin-4-yl)-ethyl]-cyclohexanone (3 g, 8.5 mmol) and ammonium acetate (25.5 g) in methanol (65 ml). The reaction mixture was stirred at room temperature for 3 hours, 0.5 g of sodium triacetoxyborohydride was added and stirring was continued for a further 2 hours. The 20 reaction mixture was diluted with NH4OH and extracted with EtOAc and dichloromethane. Organic phases were dried over MgS04 and concentrated.

O NH '2 Yield: 2.6 g, (oil), cis/trans mixture MS (EI) m/z 302 [M+H]+ 43 18.b) cis- and trans-4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol Molecular sieve, type 3A, (2.5 g) was added to a solution of 4-amino-l-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol (1250 mg, 4.14 mmol) and 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde (680 mg, 4.14 mmol) in 10 methanol (25 ml) and THF (25 ml). The reaction mixture was stirred at room temperature for 20 hours and sodium boro-hydride (157 mg, 4.14 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour and then filtered over Hydromatrix (wetted with NH4OH) and 15 subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 9/1, 1% NH40H) . cis-4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-1-20 [2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol (640 mg, 34%, MS (EI) m/z 450 [M+H]+) and trans-4-[ (2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-1-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol (360 mg, 19%, MS (EI) m/z 450 [M+H]+) were obtained. 44 Example 19: cis- and trans-6-({4-Hydroxy-4-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexylamino}-methyl)-4H-benzo[1,4]oxazin-3-one O.

N O H Sstarting from 4-amino-l-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexanol and 3-oxo-3,4-dihydro-2H-benzo- [1.4]oxazine-6-carbaldehyde, there were obtained, in a manner analogous to Example 18, cis-6-({4-hydroxy-4-[2-(6- methoxy-[1,5]naphthyridin-4-yl)-ethyl]-cyclohexylamino}-methyl)-4H-benzo[1,4]oxazin-3-one (330 mg, 17%, MS (EI) m/z 464 [M+H]+) and trans-6-({4-hydroxy-4-[2-(6-methoxy- [1.5]naphthyridin-4-yl)-ethyl]-cyclohexylamino}-methyl)-4H-benzo [1,4] oxazin-3-one (980 mg, 44%, MS (EI) m/z 464 [M+H] +) .

Example 20: cis- and trans-4-[(2, 3-Dihydro-benzo[1,4]-dioxin-6-ylmethyl)-amino]-1-[2-(6-methoxy-quinolin-4-yl) -ethyl]-cyclohexanol .a) 4-Amino-1-[2-(6-methoxy-quinolin-4-yl)-ethyl] cyclohexanol 45 4-Amino-1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol was obtained analogously to the sequence of Examples 14 and 15 starting from trifluoromethanesulphonic acid 6-methoxy-quinolin-4-yl ester and 8-ethenyl-l,4-dioxa-5 spiro[4.5]decan-8-ol. .b) 4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino] 1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol Starting from 4-amino-l-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol and 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde, there were obtained, in analogy to Example 18, cis-4-[(2,3-dihydrobenzo[1,4]dioxin-6-yl- methyl)-amino]-1-[2-(6-methoxy-quinolin-4-yl)-ethyl]- cyclohexanol (50 mg, MS (EI) m/z 449.5 [M+H]+) and trans-4-[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol (56 mg, MS (EI) m/z 449.5 [M+H]+) .

Example 21: cis- and trans-6-({4-Hydroxy-4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexylamino}-methyl)-4H-benzo-[1,4]oxazin-3-one 46 Starting from 4-amino-l-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol and 3-oxo-3,4-dihydro-2H-benzo[1,4]-oxazine-6-carbaldehyde, there were obtained, in analogy to 5 Example 18, cis-6-({4-hydroxy-4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexylamino}-methyl)-4H-benzo[1,4]oxazin-3-one (32 mg, MS (EI) m/z 462.6 [M+H]+) and trans-6- ({4-hydroxy-4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexyl-amino}-methyl)-4H-benzo[1,4]oxazin-3-one (40 mg, MS (EI) 10 m/z 462.6 [M+H]+) .

Example 22: 4-[(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]-1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol In analogy to Example 11.b, 4-[(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amino]—1—[2—(6— methoxyquinolin-4-yl)-ethyl]-cyclohexanol was obtained in 20 a yield of 72% in the form of a cis/trans mixture (MS (EI) m/z 450 [M+H]+) . 2,3-Dihydro-[1,4]dioxino[2,3-c]pyridine-7-carbaldehyde was prepared according to WO 03/010138. 47 Example 23: 4-[(Benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol Cl in analogy to Example 11.b, 4-[(benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol was obtained in a yield of 47% in the form of a cis/trans mixture (MS (EI) m/z 449 [M+H]+).

Example 24: 1-[2-(6-Methoxy-quinolin-4-yl)-ethyl]-4-(3-phenyl-allylamino)-cyclohexanol O— In analogy to Example 11.b, 1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-4-(3-phenyl-allylamino)-cyclohexanol was obtained in a yield of 46% in the form of a cis/trans mixture (MS (EI) m/z 418[M+H]+).

Example 25: 1-[2-(6-Methoxy-quinolin-4-yl)-ethyl]-4-20 [(quinoxalin-2-ylmethyl)-amino]-cyclohexanol 48 In analogy to Example 11.b, 1-[2-(6-methoxy-quinolin-4-yl)-ethyl]-4-[(quinoxalin-2-ylmethyl)-amino]-cyclohexanol was obtained in a yield of 61% in the form of a cis/trans mixture (MS (EI) m/z 443[M+H]+).

Example 26: 6-({4-Hydroxy-4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexylamino}-methyl)-2,3-dihydro-benzo[1,4]-dioxin-5-ol In analogy to Example 11.b, 6-({4-hydroxy-4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexylamino}-methyl)-2,3-dihydro-benzo[1,4]dioxin-5-ol was obtained in a yield of 19% in the form of a cis/trans mixture (MS (EI) m/z 465 [M+H] +) .

The corresponding aldehyde was prepared analogously to J. heterocycl. Chem 1989, 26, 193-197.

Example 27: 4-[(2-Chloro-quinolin-3-ylmethyl)-amino]-1-[2-(6-methoxy-quinolin~4-yl)-ethyl]-cyclohexanol \ O \ o 49 In analogy to Example 11.b, 4-[(2-chloro-quinolin-3-yl-methyl)-amino]-1-[2-(6-methoxy-quinolin-4-yl)-ethyl] -cyclohexanol was obtained in a yield of 56% in the form of a cis/trans mixture (MS (EI) m/z 477[M+H]+).

Example 28: Synthesis of 2-{4-hydroxy-4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexylamino}-N-pyridin-2-yl-acetamide 2-Bromo-N-pyridin-2-yl-acetamide (0.068 g, 0.31 mmol) and potassium carbonate (0.045 g, 0.34 mmol) were added to a solution of 4-amino-l-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanol (0.094 g, 0.31 mmol) in DMF (3.5 ml). The reaction mixture was stirred at room temperature for 2 days and then concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 19/1 1% ammonium hydroxide).

Yield: O.llg (0.25 mmol) in the form of a cis/trans mixture.

MS (EI) m/z 435 [M+H]+ 2-Bromo-N-pyridin-2-yl-acetamide has already been described in WO 02/24684. 50 Example 29: Benzo[1,3]dioxol-5-ylmethyl-{4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexyl}-amine 29.a) 8-Ethynyl-l,4-dioxa-spiro[4.5]decane: A solution of carbon tetrabromide (12.4 g, 37.4 mmol) in dichloromethane (40 ml) was added at -30°C to a solution of triphenylphosphine (19.6 g, 14.6 mmol) and 1,4-dioxa-10 spiro[4.5]dec-8-carbaldehyde (5 g, 29.37 mmol) in dichloromethane (100 ml). After the solution had been stirred at room temperature for 2 hours, it was concentrated to dryness by rotary evaporation. The residue was diluted with ethyl acetate and n-hexane (1:3; 500 ml), 15 filtered over Celite and concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (hexane/EtOAc 4/1). Yield: 6.08 g (18.6 mmol). That material was dissolved in THF (90 ml) and, at -78°C, n-BuLi (16.5 ml, 38 mmol 2. 3N in hexane) 20 was added dropwise. After the solution had been stirred at -78°C for 1 hour, a solution of 10% NaHSCU (50 ml) was added. The aqueous phase was extracted three times using 50 ml of ethyl acetate each time, dried over MgS04, filtered and concentrated to dryness by rotary 25 evaporation. The residue was purified by column chromatography on silica gel (hexane/EtOAc 5/1).

Yield: 2.74 g (16.5 mmol) 6 H (CDC13, 300 MHz): 1.61 (m, 2H) ; 1.70-1.94 (m, 6H) ; 2.07 (d, J=2.5 Hz, 1H) ; 2.51 (m, 1H) ; 3.96 (s, 30 4H). 51 29.b) 4-(1,4-Dioxaspiro[4.5]dec-8-ylethynyl)-6-methoxy-quinoline: o— A degassed solution of trifluoromethanesulphonic acid 6-methoxyquinolin-4-yl ester (0.95 g, 3.1 mmol) and 4 —(1,4 — dioxa-spiro[4.5]dec-8-ylethynyl)-6-methoxy-quinoline (0.514 g, 3.1 mmol)in DMF (6 ml) and TEA (12 ml) was added to a mixture of PdCl2(PPh3)2 (0.110 g, 0.157 mmol) and Cul 10 (0.055 g, 0.288 mmol). After the solution had been stirred at room temperature for 1 hour, it was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (EtOAc). 29.c) 4-[2-(l,4-Dioxaspiro[4.5]dec-8-yl)ethyl]-6-methoxy-quinoline : Platinum oxide ((0.462 g) was added to a solution of 4-(1,4-dioxa-spiro[4.5]dec-8-yl-ethynyl)-6-methoxyquinoline (0.83 g, 2.53 mmol) in EtOH (30 ml) and ethyl acetate (10 ml) and hydrogenation was carried out under a hydrogen atmosphere (lbar). The catalyst was filtered off and the 25 filtrate was concentrated to dryness by rotary Yield: 0.83 g (2.56 mmol) MS (EI) m/z 324 [M+H]+ O— 52 evaporation. The residue was purified by column chromatography on silica gel (EtOAc and then EtOAc/-methanol 9/1) .

Yield: 0.77 g (2.35 mmol) MS (EI) m/z 328 [M+H]+ 29.d) 4-[2-(6-Methoxy-quinolin-4-yl)-ethyl]-cyclohexanone: A solution of 4-[2-(1,4-dioxa-spiro[4.5]dec-8-yl)-ethyl]-6-methoxy-quinoline (0.77 g, 2.35 mmol) in ACOH/THF/H2O (3/2/2, 10 ml) was stirred at 60°C for 10 hours. The reaction mixture was concentrated to dryness by rotary evaporation. The residue was diluted with EtOAc (100 ml), 15 washed with NaHC03 (100 ml), dried over MgS04, filtered and concentrated to dryness by rotary evaporation.

Yield: 0.631 g (2.23 mmol) MS (EI) m/z 284 [M+H]+ 29.e) Benzo[1,3]dioxol-5-ylmethyl-{4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexyl}-amine: 53 Piperonylamine (0.038 ml, 0.3 mmol) and sodium triacetoxyborohydride (0.05 g) were added to a solution of 4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclohexanone (0.05 g, 0.17 6 mmol) in dichloromethane (0.5 ml). The 5 reaction mixture was stirred overnight and then filtered over Hydromatrix (wetted with an NaHC03 solution, 2 ml) and subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica 10 gel (EtOAc and then EtOAc:MeOH 9/1).

Yield: 0.069 g (0.165 mmol) in the form of a cis/trans mixture Example 30: 6-({4-[2-(6-Methoxy-quinolin-4-yl)-ethyl]-cyclohexylamino}-methyl)-4H-benzo[1,4]oxazin-3-one .a) 7-[(Benzyl-{4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-20 cyclohexyl}-amino)-methyl]-4H-benzo[1,4]oxazin-3-one Benzylamine (0.135 ml, 1.24 mmol) and sodium triacetoxyborohydride (0.315 g, 1.55 mmol) were added to a solution of 4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclo-25 hexanone (Example 26.e) (0.35 g, 1.23 mmol) in dichloro-ethane (8 ml). The reaction mixture was stirred for 2 hours. 3-Oxo-3,4-dihydro-2H-benzo[l,4]oxazine-6-carb- MS (EI) m/z 419 [M+H]+ 54 aldehyde (0.230g, 1.3 mmol), THF (4 ml and sodium triacetoxyborohydride (0.315 g, 1.55 mmol) was added. The reaction mixture was stirred overnight and then filtered over Hydromatrix (wetted with an NaHC03 solution, 10 ml) 5 and subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 19/1).

Yield: 0.540 g (1.0 mmol) MS (EI) m/z 536 [M+H]+ .b) 6-({4-[2-(6-Methoxy-quinolin-4-yl)-ethyl]-cyclohexylamino }-methyl)-4H-benzo[1,4]oxazin-3-one \ O % Pd(OH)2 on carbon (0.5 g) was added to a solution of 7-[(benzyl-{4-[2-(6-methoxy-quinolin-4-yl)-ethyl]-cyclo-hexyl}-amino)-methyl]-4H-benzo[1,4]oxazin-3-one (0.535 g, 1 mmol) in THF (15 ml) and MeOH (5 ml) and hydrogenation 20 was carried out under a hydrogen atmosphere (1 bar). The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 9/1 1% ammonium hydroxide).

Yield: 0.251 g (0.56 mmol) in the form of a cis/trans mixture MS (EI) m/z 446 [M+H]+ 55 Example 31: 2—{3—[(2,3-Dihydro-benzo[1,4]dioxin-6-yl-methyl)amino]pyrrolidin-l-yl}-1-(6-methoxyquinolin-4-yl)-ethanol. 31.a) Benzyl (3RS)-[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-pyrrolidine-l-carbamate Sodium bicarbonate (7 g) and chloroformic acid benzyl 10 ester (2.8 ml) were added at 0°C to a solution of 3-amino-pyrrolidine dihydrochloride (3.2 g, 20.1 mmol) in water (100 ml) and acetone (150 ml) . The reaction mixture was stirred for 10 hours and then concentrated to dryness by rotary evaporation. The residue was diluted with EtOAc 15 (100 ml) . The two phases were separated and the aqueous phase was extracted twice using 50 ml of EtOAc each time. The combined organic phases were washed with 20 ml of saturated sodium chloride solution, dried over MgS04, filtered and concentrated to dryness by rotary evapora-20 tion. The residue was dissolved in dichloromethane (30 ml), and 1,4-benzodioxane-6-carbaldehyde (1.6 g) and, after 20 minutes, sodium triacetoxyborohydride (4 g) were added. The reaction mixture was stirred overnight and then diluted with sodium bicarbonate (80 ml) . The two phases 25 were separated and the aqueous phase was extracted twice using 50 ml of dichloromethane each time. The combined organic phases were washed with 20 ml of saturated sodium chloride solution, dried over MgS04, filtered and concentrated to dryness by rotary evaporation. The residue O 56 was purified by column chromatography on silica gel (EtOAc:MeOH 9/1) .

Yield: 3.75 g (10.1 mmol) 6 H (CDC13, 300 MHz): 1.57 (br s, 1H), 1.77 (m, 1H) , 5 2.07 (m, 1H) ; 3.21 (m, 1H) ; 3.37 (m, 2H) ; 3.61 (m, 2H), 3.70 (s, 2H); 4.25 (s, 4H); 5.14 (s, 2H); 6.76-6.84 (m, 3H); 7.30-7.38 (m, 5H). 31.b) (2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)pyrrolidin-10 (3RS)-yl-amine: % Pd(OH)2 on carbon (1 g) was added to a solution of benzyl 3-[(2,3-dihydro-benzo[1,4]dioxin-6-yl-methyl)- amino]pyrrolidin-l-carbamate (3.75 g, 10.1 mmol) in EtOH (20 ml) and EtOAc (20 ml) and hydrogenation was carried out under a hydrogen atmosphere (1 bar). The reaction mixture was filtered and the filtrate was concentrated.

Yield: 2.15 g (9.2 mmol) MS (EI) m/z 235 [M+H]+ 57 31.c) 2-{(3RS)-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-pyrrolidin-l-yl}-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol: A solution of 6-methoxy-4-oxiranylquinoline (0.201 g, 1 mmol) and (2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-pyrrolidin-3-ylamine (0.234 g, 1 mmol) in ethanol (2 ml) was heated at 80°C for 16 hours. The reaction mixture was cooled to room temperature and concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (EtOAc and then EtOAc/MeOH 5:1).

Yield: 0.208 g (0.477 mmol) MS (EI) m/z 436.5 [M+H]+ Example 32: 4-(4-Methoxy-benzylamino)-1-[2-(6-methoxy-quinazolin-4-yl)-ethyl]cyclohexanol. 4-Methoxybenzylamine (0.026 ml, 0.24 mmol) and then sodium triacetoxyborohydride (0.08 g, 0.377 mmol) were added to a \ O 58 solution of 4-hydroxy-4-[2~(6-methoxyquinazolin-4-yl)-ethyl]cyclohexanone (0.06 g, 0.2 mmol) in dichloromethane (1 ml). The reaction mixture was stirred overnight and then filtered over Hydromatrix (wetted with an NaHC03 5 solution, 2 ml) and subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 9/1 and then dichloromethane/MeOH 9/1 and 2% triethylamine).

Yield:0.052 g (0.124 mmol) in the form of a cis/trans mixture MS (EI) m/z 422 [M+H]+ Example 33: 4-(3-Fluorobenzylamino)-1-[2-(6-methoxy-15 quinazolin-4-yl)-ethyl]cyclohexanol.

The compound was prepared analogously to Example 10, starting from 3-fluorobenzylamine (0.026 ml, 0.24 mmol). 20 Yield: (0.052 g, 0.124 mmol) in the form of a cis/trans mixture MS (EI) m/z 410 [M+H]+ 59 Example 34: 2-{4-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl-ethyl)-amino]-azepan-l-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol. 34.a) tert-Butyl 4-oxoazepane 1-carbamate: A mixture of 5-oxoazepane-l,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (5.7 g, 20 mmol; prepared as 10 described in Synthetic Communications 1992, 22, 1249) was refluxed for 3 hours in a mixture of 3N NaOH (50 ml) and THF (25 ml) . The reaction mixture was cooled and neutralised with dilute HC1. The mixture was extracted with ethyl acetate and the organic phases were dried over 15 MgS04 and concentrated.

Yield: 4.2 g (100%) ^-NMR (CDCI3, 300 MHz): 1.46 (s, 9H) ; 1.80 (br, 2H) ; 2.60-2.7 (m, 4H) ; 3.4-3.6 (m, 4H) . 34.b) tert-Butyl (4RS)-aminoazepane-l-carbamate: Ammonium acetate (3.5 g) and sodium cyanoborohydride (295 mg, 1 eq.) were added to a solution of tert-butyl 4-25 oxoazepane-l-carbamate (1 g, 4.68 mmol) in methanol (50 ml) . The mixture was stirred overnight at room temperature. The reaction mixture was concentrated and the residue was dissolved in saturated potassium carbonate 60 solution and ethyl acetate. The aqueous phase was extracted with ethyl acetate (2x50ml), and the combined organic phases were dried over magnesium sulphate and concentrated. 1 g (100%) of product was obtained, which 5 was further used without purification. 1H-NMR (CDC13, 300 MHz): 1.46 (s, 9H) ; 1.5-1.75 (m, 2H); 1.8-2.05 (m, 4H); 2.4 (br, 2H); 2.95-3.05 (m, 1H); 3.1-3.6 (m, 4H).

MS (EI) m/z 215.6 [M+H]+ 34.c) tert-Butyl (4RS)-[(2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-amino]-azepane-l-carbamate: Acetic acid (500 pi) and sodium cyanoborohydride (126 mg) were added to a solution of tert-butyl 4-aminoazepane-l-carbamate (428 mg, 2 mmol) and 2,3-dihydrobenzo[1,4]-dioxin-6-carbaldehyde (330 pi, 2 mmol) in dichloroethane (10 ml). The mixture was stirred overnight at room 20 temperature, diluted with saturated potassium carbonate solution and extracted with dichloromethane. The organic phases were dried over magnesium sulphate and concentrated. The product was purified by chromatography on silica gel (ethyl acetate).

Yield: 370 mg (51%) XH-NMR (CDCI3, 300 MHz): 1.46 (s, 9H) ; 1.5-1.75 (m, 2H) ; 1.8-2.05 (m, 4H) ; 2.65 (m, 1H) ; 3.1-3.6 (m, 4H) ; 3.70 (s, 2H); 4.26 (s, 4H); 6.8-6.9 (m, 3H).

MS (EI) m/z 363.6 [M+H]+ O O 61 34.d) Azepan-(4RS)-yl-(2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-amine: tert-Butyl 4-[(2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-amino]-azepane-l-carbamate (370 mg, 1 mmol) was dissolved in a mixture of 10 ml of water and 2 ml of conc. HCl and stirred at room temperature for 24 hours. The reaction mixture was neutralised with solid potassium carbonate and 10 extracted with ethyl acetate. Chromatography on silica gel (dichloromethane/MeOH 9:1) yielded 220 mg of pure product (85%). 1H-NMR (CDC13, 300 MHz): 1.8-2.0 (m, 1H); 2.0-2.3 (m, 4H); 2.3-2.6 (m, 2H); 3.2-3.4 (m, 4H) / 3.6-6.7 (m, 1H); 15 3.95 (dd, 2H); 4.2-4.3 (m, 5H); 6.8-7.1 (m, 3H).

MS (EI) m/z 263.4 [M+H]+ 34.e) 2-{(4RS)-[(2,3-Dihydrobenzo[1,4]dioxin-6-ylmethyl)-amino]-azepan-l-yl}-(IRS)-(6-methoxyquinolin-4-yl)ethanol: ylmethyl)amine (60 mg), 6-methoxy-4-oxiranyl-quinoline (50 mg) , lithium perchlorate (25 mg) and potassium carbonate (35 mg) was heated overnight at 80°C in DMF 25 (1 ml) . The reaction mixture was purified by 62 chromatography on silica gel (dichloromethane/MeOH 9:1 ( + 2% NEt3) . 1H-NMR (CDC13, 300 MHz): 1.5-2.0 (m, 7H) ; 2.45 (dd, 1H) ; 2.55-3.05 (m, 8H) ; 3.5-3.8 (m, 2H) ; 3.85 (s, 3H) ; 5 4.15 (s, 4H); 5.25-5.35 (m, 1H); 6.6-6.8 (m, 2H); 7.11 (dd, 1H) ; 7.30 (dd, 1H) ; 7.55 (dd, 1H) ; 7.97 (d, 1H) ; 8.7 (d, 1H).

MS (EI) m/z 464.6 [M+H]+ Example 35: [1-(2,3-Dihydro-benzo[1, 4]dioxin-6-yl-methyl)-azepan-4-yl](6-methoxyquinolin-4-ylmethyl)amine: .a) tert-Butyl (4RS)-[(6-methoxyquinolin-4-ylmethyl)-amino]-azepane-l-carbamate: \ O N^° o Sodium cyanoborohydride (170 mg, 2.7 mmol) was added to a solution of tert-butyl 4-aminoazepane-l-carbamate (568 mg, 2.65 mmol) and 6-methoxyquinoline-4-carbaldehyde (4 97 mg 20 (2.7 mmol) in dichloroethane (10 ml) and acetic acid (1 ml) . The reaction mixture was stirred at room temperature overnight, poured onto saturated sodium carbonate solution and extracted with dichloromethane. The organic phase was dried over magnesium sulphate and 25 concentrated. The product was purified by chromatography on silica gel (ethyl acetate).

Yield: 515 mg (51%) 63 1H-NMR (CDC13, 300 MHz): 1.47 (s, 9H); 1.5-2.0 (m, 8H); 2.8-2.9 (m, 1H) ; 3.2-3.65 (m, 5H) ; 3.97 (s, 3H) ; 4.22 (s, 2H); 5.25-5.35 (m, 1H); 6.6-6.8 (m, 2H); 7.11 (dd, 1H); 7.35-7.45 (m, 3H); 8.02 (d, J=9.2Hz, 1H); 8.73 (d, 5 J= 1. 4 H z, 1H) .

MS (EI) m/z 386.5 [M+H]+ .b) Azepan-(4RS)-yl-(6-methoxyquinolin-4-ylmethyl)amine: _ H H TFA (1 ml) was added at room temperature to a solution of tert-butyl 4-[(6-methoxyquinolin-4-ylmethyl)amino]- azepane-l-carbamate (700 mg, 1.8 mmol) in dichloromethane (1 ml). The reaction mixture was stirred at room temperature for 3 hours, concentrated and taken up in aqueous NaOH. The aqueous phase was extracted with ethyl acetate and the combined organic phases were dried over sodium sulphate. The product was purified by chromatography on silica gel (DCM/MeOH 9:1 (1% NH4OH) ) .

Yield: 477 mg (92%) XH-NMR (CDCI3, 300 MHz): 1.7-2.3 (m, 6H) ; 3.0-3.3 (m, 4H); 3.35-3.45 (m, 1H); 3.97 (s, 3H)/ 4.2 (s, 2H); 7.28 (d, 1H); 7.35-7.45 (m, 2H) ; 8.02 (d, J=9.2Hz 1H); 8.73 (d, J=1.4Hz, 1H).

MS (EI) m/z 286.3 [M+H]+ \ O 64 .c) [1-(2,3-Dihydrobenzo[1,4]dioxin-6-ylmethyl)-azepan-(4RS)-yl]-(6-methoxyquinolin-4-ylmethyl)amine: Sodium triacetoxyborohydride (100 mg, 0.47 mmol) was added to a solution of azepan-4-yl-(6-methoxyquinolin-4-yl-methyl)amine (90 mg, 0.32 mmol) and 2,3-dihydro-benzo-[1,4]dioxin-6-carbaldehyde (51.8 mg, 0.32 mmol) in dichloroethane/THF (1:1, 0.7 ml). The reaction mixture was 10 stirred at room temperature for 3 hours, concentrated and chromatographed on silica gel (ethyl acetate, methanol).

Yield: 56 mg (41%) 1H-NMR (CDC13, 300 MHz): 1.40-2.05 (m, 6H) ; 2.35-2.80 (m, 3H) ; 2.8-2.9 (m, 1H) / 3.41 (2, 2H) ; 3.99 (s, 3H) ; (dd, J=2.76, J=9.1, 1H); 7.45 (d, J=2.76, 1H); 7.51 (d, J=4.4, 1H); 7.92 (d, J=9.12, 1H) ; 8.65 (d, J=4.4, 1H) . MS (EI) m/z 434.7 [M+H]+ Example 36: (6-Methoxyquinolin-4-ylmethyl)-(1-phenethyl-azepan-(4RS)-yl)-amine: 4.15 (s, 2H) ; 4.20 (s, 4H) ; 6.70-6.80 (m, 3H) ; 7.37 65 There was also prepared in a manner analogous to Example 35.c: (6-methoxyquinolin-4-ylmethyl)-(1-phenethylazepan-(4RS)-yl)-amine (25% yield, MS (EI) m/z 390.5 [M+H] +) .

Example 37::(6-Methoxyquinolin~4-ylmethyl)-[1-(3-phenyl-propyl)-azepan-4-yl]amine There was also prepared in a manner analogous to Example 35. c: (6-methoxyquinolin-4-ylmethyl)-[1-(3-phenylpropyl)-azepan-4-yl]amine (25% yield, MS (EI) m/z 404.9 [M+H]+) Example 38: (1-Heptylazepan-(4RS)-yl)-(6-methoxyquinolin-4-ylmethyl)amine: There was also prepared in a manner analogous to Example 35.c: (1-heptylazepan-(4RS)-yl)-(6-methoxy-quinolin-4-ylmethyl)amine (43% yield, MS (EI) m/z 384.4 [M+H] +) . / 66 Example 39: l-{(4RS)-[(6-methoxyquinolin-4-ylmethyl)-amino]-azepan-l-yl}-3-phenylpropenone.

Cinnamic acid chloride (52.5 mg, 1 eq.) was added to a solution of azepan-4-yl-(6-methoxyquinolin-4-yl-methyl) -amine (90 mg, 0.32 mmol) in THF/DCE. The reaction mixture was stirred at room temperature for 3 hours, concentrated, and purified by chromatography on silica gel (DCM/MeOH 9:1 10 (+1% NH40H)) .

Yield: 37 mg (38%) MS (EI) m/z 416.6 [M+H]+ Example 40: l-[(2RS)-Hydroxy-2-(6-methoxyquinolin-4-yl)-15 ethyl]-4-phenethyl-[1,4]diazeparie-(5RS)-carboxylic acid tert-butyl ester 40.a) 1-[2-Hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]-[1,4]-diazepane-5-carboxylic acid tert-butyl ester A mixture of 6-methoxy-4-oxiranylquinoline (400 mg, 2 mmol), [1,4]-diazepane-5-carboxylic acid tert-butyl O Intellectual Property Office of N.Z. - 5 MAY 2005 67 ester (400 mg, 2 mmol, prepared as described in J. Chem. Research (S) , 1991, 306, 2876), lithium perchlorate (211 mg, 2 mmol) and potassium carbonate (275 mg, 2 mmol) in DMF (5 ml) was heated at 100°C for 4 hours. The 5 reaction mixture was diluted with water and ethyl acetate, the aqueous phase was extracted with ethyl acetate and the combined organic phases were dried over sodium sulphate and concentrated. The product was purified by chromatography on silica gel (DCM/MeOH 9:1). 10 Yield: 330 mg (41%) MS (EI) m/z 402.5 [M+H]+ 40.b) 1-[(2RS)-Hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]-4-phenethyl-[1,4]diazepane-(5RS)-carboxylic acid tert-butyl 15 ester: Sodium triacetoxyborohydride (79 mg (1.5 eq) was added to a solution of 1-[2-hydroxy-2-(6-methoxy-quinolin-4-yl)-20 ethyl]-[1,4]diazepane-5-carboxylic acid tert-butyl ester (100 mg, 0.25 mmol) and phenyl acetaldehyde (29.2 |al, 1 eq.) in THF (700 jxl) . After 2 hours, a further equivalent of phenyl acetaldehyde was added and the reaction mixture was heated to 40°C. After a further 25 2 hours, the reaction mixture was concentrated to dryness and purified by chromatography on silica gel (ethyl acetate, methanol). \ 68 Yield: 67 mg (54%) MS (EI) m/z 506 [M+H]+ 40.c) 1-[(2RS)-Hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl] -4-phenethyl-[1,4]-diazepane-(5RS)-carboxylic acid: 1-[2-Hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-4-phenethyl-[1,4]diazepane-5-carboxylic acid tert-butyl ester (55 mg) was suspended in 4M HC1 in dioxane and stirred at room temperature for 3.5 hours. The reaction mixture was concentrated and purified by preparative HPLC. Yield: 3.9 mg MS (EI) m/z 450 [M+H]+ The following were also synthesised in analogous manner: 40.d) 1-[2-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-4-(3-phenylpropyl)-[1,4]diazepane-5-carboxylic acid tert-butyl ester and 40.e) 1-[2-hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]-4-(3-phenylpropyl)-[1,4]diazepane-5-carboxylic acid starting from dihydrocinnamaldehyde.

In the same way, 40.f) 4-heptyl-l-[2-hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-[1,4]diazepane-5-carboxylic acid tert-butyl ester and 40.g) 4-heptyl-l-[2-hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-[1,4]diazepane-5-carboxylic acid \ 69 were prepared starting from heptanal.

Example 41: 2-[(RS)5-Hydroxymethyl-4-(3-phenylpropyl)-[1,4]diazepan-l-yl]-(IRS)-(6-methoxyquinolin-4-yl)-5 ethanol.

\ O Lithium aluminium hydride (28 mg) was added to a solution of 1-[2-hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-4-(3-phenylpropyl)-[1,4]-diazepane-5-carboxylic acid tert-butyl 10 ester (80 mg) in THF and stirring was carried out at room temperature for 1 hour. A few drops of saturated Rochelle salt solution were added to the reaction mixture, stirring was carried out for 15 minutes and the precipitate was filtered off.

Yield: 39 mg (57%) MS (EI) m/z 450 [M+H]+ Starting from 4-heptyl-l-[2-hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-[1,4]diazepane-5-carboxylic acid tert-butyl 20 ester, 2-(4-heptyl-5-hydroxy-methyl-[1,4]-diazepan-l-yl)-1-(6-methoxyquinolin-4-yl)-ethanol was produced in an analogous manner in a yield of 33% (MS (EI) m/z 430 [M+H] +) . 70 Example 42: (2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-[4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexyl]-amine 42.a) 4-(6-Methoxy-quinazolin-4-yloxymethyl)-cyclohexanol Sodium hydride (79 mg (1.5 eq.) was added at 0°C to a solution of 4-hydroxymethyl-cyclohexanol (3 g, 12 mmol, synthesised analogously to J.Org.Chem. 1994 59 p. 2748-2761) in DMF (30 ml). After 20 minutes, a solution of 10 4-chloro-6-methoxy-quinazoline (1.94 g, 10 mmol) in DMF (10 ml) was added and the reaction mixture was heated to 40°C. After a further 2 hours, the reaction mixture was concentrated to dryness. The residue was diluted with water (100 ml) and ethyl acetate (100 ml), the phases were 15 separated and the aqueous phase was extracted twice using 50 ml of ethyl acetate each time. The combined organic phases were dried over MgSCU, filtered and concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (EtOAc/hexane 1/2). 20 Yield: 2.01 g, 7 mmol (54%) MS (EI) m/z 289 [M+H]+ 42.b) 4-(6-Methoxy-quinazolin-4-yloxymethyl)-cyclohexanone ,OH 71 Triethylamine (10 ml, 71 mmol) and then, in portions, Pyr.S03 (5.8 g, 36 mmol), were added at 0°C to a solution of 4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexanol (2.88 g, 10 mmol) in DMSO (30 ml). The reaction mixture 5 was stirred at that temperature for 15 minutes and then allowed to come to room temperature. After 2 hours, water (300 ml) was added. The aqueous phase was extracted with ether (3 x 150 ml) . The combined organic phases were washed with saturated sodium chloride solution, dried over 10 MgS04 and concentrated. The crude product was purified by chromatography on silica gel (EtOAc/hex 1/2).

Yield: 2.6 g, 9.1 mmol MS (EI) m/z 287.1 [M+H]+ 42.c) Benzyl-[4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexyl]-amine Benzylamine (1.08 ml, 10 mmol) and sodium cyanoborohydride (2.2 g, 11 mmol) were added to a solution of 4-(6-methoxy-20 quinazolin-4-yloxymethyl)-cyclohexanone (2.87 g, 10 mmol) in methanol (50 ml) . The mixture was stirred overnight at room temperature. The reaction mixture was concentrated and the residue was dissolved in saturated potassium carbonate solution and ethyl acetate. The aqueous phase 25 was extracted with ethyl acetate (2x50ml), and the combined organic phases were dried over magnesium sulphate and concentrated. The residue was purified by column 72 chromatography on silica gel (EtOAc and then EtOAc/MeOH 9/1) .

Yield: 2.87 g, 10 mmol in the form of a cis/trans mixture 42.d) 4-(6-Methoxy-quinazolin-4-yloxymethyl)-cyclohexyl- 20% Pd(OH)2 on carbon (1 g) was added to a solution of benzyl-[4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexyl] -amine (2 g, 5.3 mmol) in MeOH (30 ml) and hydrogenation was carried out under a hydrogen atmosphere (1 bar) at 65°C. The reaction mixture was filtered and the 15 filtrate was concentrated.

Yield: 1.44 g , 5 mmol in the form of a cis/trans mixture MS (EI) m/z 288 [M+H]+ 42.e) Title compound \ O MS (EI) m/z 287.1 [M+H]+ amine 2,3-Dihydro-benzo[1,4]dioxin-6-carbaldehyde (0.045 g, 0.27 mmol) and then sodium triacetoxyborohydride (0.08 g, 73 0.377 mmol) were added to a solution of 4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexylamine (0.07 g, 0.25 mmol) in dichloroethane (1 ml). The reaction mixture was stirred for 2 hours and then filtered over Hydromatrix 5 (wetted with NaHC03 solution, 2 ml) and subsequently washed with dichloromethane. The filtrate was concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloro-methane/MeOH 9/1 and then dichloromethane/MeOH 6/1).

Yield: 0.02g (0.04 6 mmol) in the form of a cis/trans mixture MS (EI) m/z 436 [M+H]+ Example 43: [4-(6-Methoxy-quinazolin-4-yloxymethyl)-15 cyclohexyl]-quinoxalin-2-ylmethyl-amine \ In analogy to Example 42.e, [4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexyl]-quinoxalin-2-ylmethylamine was produced in a yield of 31% in the form of a cis/trans 20 mixture (MS (EI) m/z 430 [M+H]+). 74 # Example 44: 6-{[4-(6-Methoxy-quinazolin-4-yloxymethyl)-cyclohexylamino]-methyl}-4H-benzo[1,4]oxazin-3-one In analogy to Example 42.e, 6-{[4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexylamino]-methyl}-4H-benzo[1,4]oxazin-3-one was produced in a yield of 38% in the form of a cis/trans mixture (MS (EI) m/z 448 [M+H]+).

Example 45: [4-(6-Methoxy-quinazolin-4-yloxymethyl)-cyclohexyl]-(3-phenyl-allyl)-amine In analogy to Example 42.e, [4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexyl]-(3-phenyl-allyl)-amine was produced in a yield of 25% in the form of a cis/trans mixture (MS (EI) m/z 405 [M+H]+).

\ O 75 Example 46: 2-[4-(6-Methoxy-quinazolin-4-yloxymethyl)-cyclohexylamino]-N-pyridin-2-yl-acetamide 2-Bromo-N-pyridin-2-yl-acetamide (0.075 g, 0.35 mmol) and potassium carbonate (0.054 g, 0.39 mmol) were added to a solution of 4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclo-hexylamine (0.1 g, 0.35 mmol) in DMF (3.5 ml). The reaction mixture was stirred at room temperature for 2 days and then concentrated to dryness by rotary evaporation. The residue was purified by column chromatography on silica gel (dichloromethane/MeOH 19/1 1% NH4OH). Yield: 0.086 g (0.2 mmol) in the form of a cis/trans mixture MS (EI) m/z 422 [M+H]+ Example 47: (2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-[4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexyl]-amine Starting from Example 42.e, was produced in an analogous manner in a yield of 55% in the form of a cis/trans mixture (MS (EI) m/z 437 [M+H]+).

O O 76 Example 48: (2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-[4-(6-methoxy-quinolin-4-yloxymethyl)-cyclohexyl]-amine 48 . a) trans-4-tert-Butoxycarbonylamino-cyclohexane-5 carboxylic acid -vCrYV o Di-tert-butyl dicarbonate (12 g, 55 mmol) dissolved in dioxane (50 ml) was added dropwise to a solution of trans-4-aminocyclohexanecarboxylic acid (Synth. Commun. 2002, 10 32, 1985) (7.16 g, 50 mmol) in dioxane (50 ml) and water (50 ml) . After stirring for 30 minutes at room temperature, 1M NaOH (50 ml) was added and the reaction mixture was stirred overnight at room temperature. The dioxane was distilled off using a rotary evaporator and 15 the aqueous residue was adjusted to pH 3 using IN HC1 and extracted with ethyl acetate. Organic extracts dried over Na2S04 and concentrated.

Yield: 13.2 g MS (EI) m/z 242.4 [M-H]") . 48.b) tert-Butyl trans-(4-hydroxymethyl-cyclohexyl)-carbamate fYV°V A solution of borane dimethyl sulphide complex (2.85 ml, 25 30 mmol) in THF (50 ml) was added dropwise at 0°C to a solution of trans-4-tert-butoxycarbonylamino-cyclohexane-carboxylic acid (2.43 g, 10 mmol) in THF (100 ml) . The 77 reaction mixture was stirred at 0°C for 15 minutes and at room temperature for 3 hours, methanol was cautiously added and the mixture was concentrated. The crude product was repeatedly treated with methanol and concentrated 5 again, and finally dried under a high vacuum. Used without further purification.

Yield: 2.4 g (quant.) 48.c) trans-Methanesulphonic acid 4-tert-butoxycarbonyl-10 aminocyclohexylmethyl ester At 0°C, triethylamine (417 fil, 2.2 mmol) was added to a solution of tert-butyl trans-(4-hydroxymethylcyclohexyl)-carbamate (459 mg, 3 mmol) in dichloromethane (25 ml), and 15 methanesulphonyl chloride (171 fil, 2.2 mmol) was added dropwise. The reaction mixture was stirred at 0°C for 5 hours and at room temperature for 1 hour, taken up with water and extracted with dichloromethane. The organic phase was dried over Na2S04 and concentrated. The crude 20 product was reacted without further purification. 78 48.d) tert-Butyl [4-(6-methoxy-quinolin-4-yloxymethyl)-cyclohexyl]carbamate N^> NaH dispersion (55% in mineral oil, 88 mg, 2 mmol) was 5 added to a suspension of 6-methoxy-4-hydroxyquinoline (350 mg, 2 mmol) in DMF (4 ml) and stirred at room temperature until a solution formed. trans-Methane-sulphonic acid 4-tert-butoxycarbonylaminocyclohexylmethyl ester (635 mg, 2 mmol) was added and the reaction mixture 10 was stirred overnight at 80°C. Water was added to the mixture and extraction was carried out with ethyl acetate. Organic extracts washed with water, dried over Na2S04 and concentrated. The crude product was purified by chromatography on silica gel (DCM/MeOH 9:1). 15 Yield: 438 mg, 56.6% (oil) (MS (EI) m/z 387 [M+H]+) . 48.e) tran's-4-(6-Methoxy-quinolin-4-yloxymethyl)-cyclo-hexylamine A solution of tert-butyl [4-(6-methoxy-quinolin-4-yloxy-methyl)-cyclohexyl]carbamate (438 mg, 1.13 mmol) and TFA (1.5 ml) in dichloromethane (4 ml) was stirred at room temperature for 2 hours. The reaction mixture was poured 79 onto ice/ammonium hydroxide and extracted with dichloromethane. The organic extracts were dried over Na2S04 and concentrated.

Yield: 313 mg, 97% (MS (EI) m/z 287 [M+H]+). 48.f) Title compound In analogy to Example 42.e, trans-2,3-dihydro-benzo[1,4] -dioxin-6-ylmethyl)-[4-(6-methoxy-quinolin-4-yloxymethyl) • cyclohexyl]-amine was produced in a yield of 73% (MS (EI] m/z 435 [M+H]+) .

Example 49: 6-{[4-(6-Methoxy-quinoIin-4-yloxymethyl)-cyclohexylamino]-methyl}-4H-benzo[1,4]oxazin-3-one N^O H In analogy to Example 42.e, trans-6-{[4-(6-methoxy-quinolin-4-yloxymethyl)-cyclohexylamino]-methyl}-4H-benzo-[ 1,4] oxazin-3-one was produced in a yield of 81% (MS (EI) m/z 448 [M+H]+) . 80 Example 50: (2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-[4-(6-methoxy-[1,5]naphthyridin-4-yloxymethyl)-cyclohexyl]- amine 50.a) 4-(6-Methoxy-[1,5]naphthyridin-4-yloxymethyl)-cyclo-hexylamine . NH2 4-(6-Methoxy-[1,5]naphthyridin-4-yloxymethyl)cyclohexyl-amine was prepared analogously to Example 4 8 starting from 6-methoxy-[1,5]naphthyridin-4-ol. 50.b) Title compound In analogy to Example 42.e, (2,3-dihydro-benzo[1,4]dioxin-15 6-ylmethyl)-[4-(6-methoxy-[1,5]naphthyridin-4-yloxy- methyl)-cyclohexyl]-amine was produced in a yield of 55% (MS (EI) m/z 456.6 [M+H]+). 81 Example 51: 6-{[4-(6-Methoxy-[1,5]naphthyridin-4-yloxy-methyl)-cyclohexylamino]-methyl}-4H-benzo[1,4]oxazin-3-one In analogy to Example 42.e, trans-6~{[4-(6-methoxy-[1,5]naphthyridin-4-yloxymethyl)-cyclohexylamino]-methyl}-4H-benzo[1,4]oxazin-3-one was produced in a yield of 79% (MS (EI) m/z 456.6 [M+H]+).

Example 52: 2-{3-[(2,3-Dihydro-benzo[1,4]dioxin-6-yl-methyl)-amino]-8-aza-bicyclo[3.2.1]oct-8-yl}-(IRS)-(6-methoxy-guinolin-4-yl)-ethanol 52.a) tert-Butyl {8-[(2RS)-hydroxy-2-(6-methoxy-quinolin-15 4-yl)-ethyl]-8-aza-bicyclo[3.2.1]oct-3-yl}carbamate \ O In analogy to Example 2.c, the title compound was produced in a yield of 82% (MS (EI) m/z 428 [M+H]+). tert-Butyl (8-aza-bicyclo[3.2.1]oct-3-yl)carbamate was prepared according to Eur. J. Med. Chem. 1991 (34) p. 646-653. 82 52.b) 2—{3—[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-8-aza-bicyclo[3.2.1]oct-8-yl}-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol \ in a yield of 86% (MS (EI) m/z 328 [M+H]+).

Example 53: 2-{3-[(Benzo[1,3]dioxol-5-ylmethyl)-aminoj-8-10 aza-bicyclo[3.2.1]oct-8-yl}-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol \ O In analogy to Example 2.e, 2-{3-[(benzo[1,3]dioxol-5-15 ylmethyl)-amino]-8-aza-bicyclo[3.2.1]oct-8-yl}—1—(6— methoxy-quinolin-4-yl)-ethanol was produced in a yield of 62% (MS (EI) m/z 462 [M+H]+). 83 Example 54: 6-({8-[(2RS)-Hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-8-aza-bicyclo[3.2.1]oct-3-ylamino}-methyl)-4H-benzo[1,4]oxazin-3-one In analogy to Example 2.e, 6-({8-[2-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-8-aza-bicyclo[3.2.1]oct-3-ylamino}-methyl)-4H-benzo[1,4]oxazin-3-one was produced in a yield of 7% (MS (EI) m/z 489 [M+H]+).

Example 55: 2-{3-[(Benzo[1, 2, 5]thiadiazol-5-ylmethyl)-amino]-8-aza-bicyclo[3.2.1]oct-8-yl}-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol In analogy to Example 2.e, 2-{3-[(benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-8-aza-bicyclo[3.2.1]oct-8-yl}—1—(6— methoxy-quinolin-4-yl)-ethanol was produced in a yield of 59% (MS (EI) m/z 476 [M+H]+). \ 0 84 Example 56: 1-(6-Methoxy-quinolin-4-yl)-2-[3-(3-phenyl-allylamino)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethanol In analogy to Example 2.e, 1-(6-methoxy-quinolin-4-yl)-2-[3-(3-phenyl-allylamino)-8-aza-bicyclo[3.2.1]oct-8-yl]-ethanol was produced in a yield of 44% (MS (EI) m/z 445 [M+H] +) .

Example 57: 2-[3-(3-Furan-2-yl-allylamino)-8-aza-bicyclo [3.2.1]oct-8-yl]-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol In analogy to Example 2.e, 2-[3-(3-furan-2-yl-allylamino)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-(6-methoxy-quinolin-4-yl)-ethanol was produced in a yield of 51% (MS (EI) m/z 434 [M+H] +) .

\ O 85 Example 58: 2-{3-[(Benzofuran-2-ylmethyl)-amino]-8-aza-bicyclo [3.2.1]oct-8-yl}-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol In analogy to Example 2.e, 2-{3-[(benzofuran-2-ylmethyl)-amino]-8-aza-bicyclo[3.2.1]oct-8-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol was produced in a yield of 62% (MS (EI) m/z 458 [M+H]+) .

Example 59: 2-(5-{[(2,3-Dihydro-benzo[1,4]dioxin-6- ylmethyl)-amino]-methyl}-3,6-dihydro-2H-pyridin-l-yl)-1-(6-methoxy-quinolin-4-yl)-ethanol 59.a) tert-Butyl 5-azidomethyl-3,6-dihydro-2H-pyridine-l-15 carbamate At 0°C, triethylamine (3.7 ml, 26.2 mmol) and, dropwise, methanesulphonyl chloride (1.2 ml, 15.44 mmol) were added 20 to a solution of tert-butyl 5-hydroxymethyl-3,6-dihydro-2H-pyridine-1-carbamate (Tetrahedron 1998, 54, 7045-7056, 2.8 g, 13.1 mmol) in DCM (50 ml). The reaction mixture was stirred at 0°C for 20 minutes before a saturated solution of NaHC03 (40 ml) was added, and the two phases were \ O 86 separated. The aqueous phase was extracted with dichloromethane (40 ml) . The combined organic phases were washed with saturated sodium chloride solution and dried over MgS04 and concentrated. The crude product was dissolved in 5 DMF (50 ml), and sodium azide (1.7 g, 26.1 mmol) was added. The mixture was heated to 80°C. Reaction monitored by LCMS. Once the reaction was complete, the mixture was cooled and concentrated. The residue was taken up in EtOAc and water and the aqueous phase was extracted with EtOAc 10 (2 x 100 ml). The combined organic phases were washed with saturated sodium chloride solution, dried over MgS04 and concentrated. The residue was purified by chromatography on silica gel (EtOAc/hex 1/6). 59.b) tert-Butyl 5-aminomethyl-3, 6-dihydro-2H-pyridine-l-carbamate Triphenylphosphine on polystyrene (5.24 g) was added to a solution of tert-butyl 5-azidomethyl-3,6-dihydro-2H-pyridine-l-carbamate (1 g, 4.2 mmol) in THF (25 ml) and water (0.250 ml). The reaction mixture was shaken at room temperature for 36 hours. The polymer was filtered off and 25 then washed with THF. The filtrate was concentrated.

Yield: (2.2 g, 9.23 mmol) Oil. 15 MS (EI) m/z 239.4 [M+H]+.

Yield: (0.893 g, 4.2 mmol) MS (EI) m/z 213.4 [M+H]+. 87 59.c) tert-Butyl 5-{[(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-methyl}-3,6-dihydro-2H-pyridine-l-carbamate A solution of tert-butyl 5-aminomethyl-3,6-dihydro-2H-pyridine-1-carbamate (0.7 g, 3.3 mmol) and 1,4-benzo-dioxane-6-carbaldehyde (0.54 g, 3.3 mmol) in THF (2 ml) and DCE (4 ml) was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (0.770 g, 3.81 mmol) was then 10 added thereto. The reaction mixture was stirred at room temperature for 5 hours and filtered through Hydromatrix (wetted with saturated NaHC03 solution) and the filtrate was concentrated. The residue was purified by chromatography on silica gel (EtOAc/hex 2/1 and then 15 EtOAc/MeOH 9/1).

Yield: 0.16 g, 0.44 mmol (oil).

MS (EI) m/z 361 [M+H]+. 59.d) (2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-(1,2,5,6-20 tetrahydropyridin-3-ylmethyl)-amine A solution of tert-butyl 5-{[(2, 3-dihydro-benzo[1,4]-dioxin-6-ylmethyl)-amino]-methyl}-3, 6-dihydro-2H-pyridine-25 1-carbamate (0.16 g, 0.44 mmol) in TFA (3 ml) was stirred at room temperature for 30 minutes, concentrated and taken up in saturated bicarbonate solution (30 ml) and H 88 dichloromethane (30 ml) . The aqueous phase was extracted with dichloromethane (2 x 30 ml) and the combined organic phases were washed with saturated sodium chloride solution, dried over MgS04 and concentrated.

Yield: 0.06 g, 0.23 mmol, 52%(oil) MS (EI) m/z 261 [M+H]+. 59.e) Title compound A solution of (2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-(1,2,5,6-tetrahydro-pyridin-3-ylmethyl)-amine (0.06 g, 0.23 mmol) and 6-methoxy-4-oxiranylquinoline (0.06 g, 0.29 mmol) in EtOH (2 ml) was heated at 80°C for 14 hours. The reaction mixture was concentrated and the residue was 15 purified by chromatography on silica gel (DCM/MeOH 9/1).

\ O Yield: 0.025 g, 0.054 mmol, 23% (foam) MS (EI) m/z 462 [M+H]+. 89 Example 60: 2-((2RS)-{[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-methyl}-morpholin-4-yl)-(IRS)-(6-methoxy-quinolin-4-yl)-ethanol 60.a) (2RS)-Azidomethyl-4-benzyl-morpholine At 0°C, triethylamine (4.88 g, 48.25 mmol) and, dropwise, methansulphonyl chloride (2.25 ml, 28.95 mmol) were added to a solution of N-benzyl-2-hydroxymethylmorpholine 10 (Synthetic Communications, 1980, 10(1), 59-73, 5 g, 24.12 mmol) in DCM (60 ml). After 30 minutes, the reaction was terminated by addition of saturated bicarbonate solution (50 ml). The organic phase was washed with saturated sodium chloride solution (50 ml) , dried over 15 MgS04 and concentrated.

The crude product was dissolved in DMF (50 ml), and sodium azide (3.11 g, 47.8 mmol) was added. The mixture was heated overnight at 80°C. The mixture was cooled and concentrated. The residue was taken up in ether (100 ml) 20 and water (50 ml) and the aqueous phase was extracted with ether (2 x 100 ml) . The combined organic phases were washed with saturated sodium chloride solution, dried over MgS04 and concentrated. The residue was purified by chromatography on silica gel (EtOAc).

Yield: (4.23 g, 18 mmol, 75%) Oil.

MS (EI) m/z 236.2 [M+H]+. . 90 60.b) 2-(4-Benzyl-morpholin-(2RS)-yl)-methylamine NH. '2 c °y' N A solution of 2-Azidomethyl-4-benzyl-morpholine (4,23 g, 18 raraol) and triphenylphosphine (9.47 g, 36 mmol) in THF/water (10/1, 100 ml) was heated overnight at 60°C. The reaction mixture was concentrated and the residue was taken up in 3N HC1 (200 ml) and EtOAc (200 ml) . The 10 aqueous phase was extracted with EtOAc (4*). The aqueous phase was adjusted to pH 12 using NaOH and extracted with EtOAc (2 x 200 ml), dried over MgS04 and concentrated.

Yield: (3.64 g, 16.8 mmol, 93%) Oil. MS (EI) m/z 207.2 [M+H]+. 60.c) tert-Butyl (4-benzyl-morpholin-(2RS)-ylmethyl)- carbamate O At 0°C, triethylamine (1.78 g, 17.74 mmol) and di-tert-20 butyl dicarbonate (2.32 g, 10.65 mmol) were added to a solution of 2-(4-benzyl-morpholin-2-yl)-methylamine 91 (1.83 g, 8.87 mmol) in DCM (45 ml). The reaction mixture was stirred at that temperature for 30 minutes and concentrated. The residue was purified by chromatography on silica gel (EtOAc/hex 1:1).

Yield: (1.51 g, 4.93 mmol, 51%) Oil.

MS (EI) m/z 307.3 [M+H]+. 60.d) tert-Butyl {4-[(2RS)-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-morpholin-(2RS)-ylmethyl}carbamate N % Pd(OH)2 (0.7 g) was added to a solution of tert-butyl (4-benzyl-morpholin-2-ylmethyl)carbamate (1.51 g, 4.93 mmol) in THF:MeOH (1/1, 28 ml). The reaction mixture was stirred for 2 hours under a hydrogen atmosphere. The 15 mixture was filtered and the filtrate was concentrated. The intermediate was dissolved in DMF (15 ml), and 6-methoxy-4-oxiranylquinoline (0.9 g, 4.48 mmol), lithium perchlorate (0.477 g, 4.48 mmol) and potassium carbonate (0.743 g, 5.376 mmol) were added. The mixture was heated 20 at 80°C for 23 hours. After cooling, filtration was carried out and the filtrate was concentrated. The residue was dissolved in EtOAc and washed with water, dried over MgS04 and concentrated. The residue was purified by chromatography on silica gel (DCM:MeOH 9:1). 92 Yield: (1 g, 2.4 mmol, 48%) Oil.

MS (EI) m/z 418.5 [M+H]+. 60.e) 2-((2RS)-Aminomethyl-morpholin-4-yl)-(IRS)-(6-5 methoxy-quinolin-4-yl)-ethanol TFA (2.5 ml) was added at 0°C to a solution of tert-butyl {4-[2-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-morph-olin-2-ylmethyl}carbamate (0.95 g, 2.27 mmol) in DCM 10 (4 ml) . The reaction mixture was stirred at room temperature for 1.5 hours and concentrated. The residue was taken up in DCM/MeOH (9/1, 30 ml) and ammonium hydroxide (20 ml). The aqueous phase was extracted with DCM/MeOH (2 x 30 ml) and the combined organic phases were 15 dried over Na2S04 and concentrated.

NH, '2 o Yield: (0.718 g, 2.25 mmol, 99%) Oil. MS (EI) m/z 318.5 [M+H]+. 93 60.f) 2 —(2 —{[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-methyl}-morpholin-4-yl)-1-(6-methoxy-quinolin-4-yl)-ethanol Activated 3A molecular sieve (3.485 g) and piperonal 5 (0.172 g, 1.15 mmol) were added to a solution of 2-(2-aminomethyl-morpholin-4-yl)-1~(6-methoxy-quinolin-4-yl)-ethanol (0.365 g, 1.15 mmol) in DCM (10.5 ml) and methanol (3.5 ml). The mixture was stirred overnight at room temperature before sodium borohydride (0.112 g, 2.9 mmol) 10 was added. The reaction mixture was stirred at room temperature for a further 2 hours, filtered over Hydromatrix (wetted with NaHCC>3) and concentrated. The residue was purified by chromatography on silica gel (DCM:MeOH 9:1+ 1% NH4OH).

Yield: (0.261 g, 0.57 mmol, 50%) Oil.

MS (EI) m/z 452.5 [M+H]+.

Example 61: 2-((2RS)-{[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-methyl)-morpholin-4-yl)-(IRS)-(6-methoxy-20 quinolin-4-yl)-ethanol Analogously to Example 60.f, also 2-(2-{[(2,3-dihydro-benzo [1,4]dioxin-6-ylmethyl)-amino]-methyl}-morpholin-4-

Claims (1)

1. 94 yl)-1-(6-methoxy-quinolin-4-yl)-ethanol was produced in a yield of 33% (MS (EI) m/z 466 [M+H]+.) Anti-bacterial activity: 5 The MHK (|j,g/ml) of those compounds was measured in relation to the following bacterial strains: S. aureus ATCC 29213, S. aureus 16, E. faecalis ATCC 29212, E. faecium vanA E25-1, H. influenzae 11, E. coli ATCC 10 25922, M. catarrhalis 117, S. pneumoniae ATCC 49619. Examples 5-6, 8, 11-16, 18-26, 30, 44-45, 47-58 have an MHK<=0.125 in relation to at least one of the listed strains. Examples 1-4, 7, 9-10, 17, 27-29, 34, 42, 43, 46, 59, 61 15 have a MHK<=0.5 in relation to at least one of the listed strains. 95 5 What we claim is: 1. A compound of formula (I): A^R3 1 Vy4 X^xf^N'-X3 *2 (") wherein A is an oxygen, sulphur or nitrogen atom or a 10 Ci-4alkylene, C2_4alkenylene, C2_4alkynylene or Ci_4heteroalkylene group, Xi, X2, X3, X4 and X5 are each independently of the others nitrogen atoms or groups of formula CR , 15 R1 is a hydrogen atom, a halogen atom, a hydroxy group, a C^alkyloxy group or a Ci.gheteroalkyloxy group, R2 is a hydrogen atom, a halogen atom, or a 20 Ci.galkyl, C2_6alkenyl, C2.6alkynyl or a Ca.6heteroalkyl group, R3 is selected from the following groups: -t-N . N-R5 -f" N )—R R R n n n INTELLECTUAL PROPERTY OFFICE OF N.2. -8 JAN 2008 received 96 . r~{ y-N n n n n n r the radicals R4, each independently of any other(s), are a hydroxy group, a Ci_6alkyl group or a Ci-eheteroalkyl group, R5 is a Chalky!, C2_12alkenyl, C2_12alkynyl, heteroalkylcycloalkyl, C3.10heterocycloalkyl, aralkyl or heteroaralkyl radical, n is 0, 1 or 2 and m is 0 or 2, or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof. A compound according to claim 1, wherein A is an oxygen atom or a group of formula CH2 or CH(OH) . Ci.^heteroalkyl, C3_10cycloalkyl, C6-i4aryl, C6.14heteroaryl, alkylcycloalkyl, A compound according to claim 1 or 2, wherein one of the groups Xx, X2, X3, X4 and X5 is a nitrogen atom 97 and the others are CH groups, or all of the groups Xi, X2, X3, X4 and X5 are CH groups. 4. A compound according to any one of claims 1 to 3, 5 wherein R1 is a halogen atom, a Ci_6alkyloxy group, a methyl group or an ethyl group. 5. A compound according to any one of claims 1 to 4, wherein R1 is a methoxy group. 10 A compound according to any one of claims 1 to 5, wherein R4 is a Ci-6heteroalkyl group having one or two oxygen atoms as individual hetero atoms. 15 7. A compound according to any one of claims 1 to 6, wherein R4 is a group of formula -C00H, -CH2COOH, -CH2CH2COOH, -CH2COOCH3, -CH2CH3, -CH20H, -CH2CH2OH, -OH, -OCH3, -CH2OCONH2, -CH2CH2COOCH3, -COOCH3, -CH3 or -(CH2)3OH. 20 8. A compound according to any one of claims 1 to 7, wherein n is 0 or 1. 9. A compound according to any one of claims 1 to 8, 25 wherein R5 is an aralkyl group or a heteroaralkyl group. 10. A compound according to any one of claims 1 to 9, wherein R5 is a group of formula -Y-Cy, Y being a 30 Ci-C6alkylene, C2~C6alkenylene or Ci-C6heteroalkylene group, wherein optionally a hydrogen atom may have been replaced by a hydroxy group or two hydrogen INTELLECTUAL PROPERTY OFFICE OF N.2. - 9 JAN 2008 B P" A r 111 r i-v 98 atoms may have been replaced by an =0 group, and Cy being an optionally substituted phenyl, naphthyl or heteroaryl group containing 1 or 2 rings and from 5 to 10 ring atoms, or an optionally substituted arylheterocycloalkyl or heteroarylheterocycloalkyl group containing two rings and 9 or 10 ring atoms. A compound according to any one of claims 1 to 10, wherein R3 is selected from the following groups: A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 and, optionally, one or more carrier substances and/or adjuvants. Use of a compound or of a pharmaceutical composition according to any one of claims 1 to 12 in the preparation of a medicament for the treatment of bacterial infections. A compound according to claim 1, substantially as herein described or exemplified. A pharmaceutical composition according to claim 12, substantially as herein described or exemplified. A use according to claim 13, substantially as herein described or exemplified. R ,5 INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 JAN 2008 received